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Abstract 
Acetaminophen (APAP) overdose is the leading cause of acute liver failure in the US.  
APAP is metabolized to a reactive metabolite that causes hepatotoxicity in a dose-
dependent manner.  A series of cascading intracellular events lead to cellular necrosis; 
this necrosis initiates a sterile inflammatory response which includes the production of 
multiple cytokines and chemokines that in turn recruit innate immune cells into the liver.  
Many of the inflammatory or corresponding anti-inflammatory mediators that are 
produced in this process have been linked to alterations in the subsequent injury as well 
as the injury resolution.  This dissertation focuses on one particular inflammatory 
mediator, interleukin-1β (IL-1β), and its ability to modulate neutrophil priming, activation 
and hepatic recruitment.  We show that mature IL-1β is produced during APAP 
overdose in a caspase dependent manner (Nalp3 inflammasome) which can be 
inhibited in vivo by a pan-caspase inhibitor, and that IL-1β is capable of activating 
neutrophils in vivo. However, the limited amount of IL-1β produced during APAP 
overdose is insufficient to activate or recruit neutrophils into the liver. In confirmation of 
these findings, genetic elimination of the components of the Nalp3 inflammasome or the 
IL-1 receptor does not alter APAP-induced injury or neutrophil recruitment.  It has 
previously been shown that neutrophils do not participate in APAP-induced injury.  This 
has been demonstrated in various ways, however, controversy arose when 
pretreatment of mice with neutropenia-inducing antibody resulted in protection from 
APAP toxicity.  To further clarify this matter, CD18-deficient mice were subjected to 
APAP overdose, and in agreement with previous findings these mice were not protected 
from APAP overdose.  Next we functionally characterized neutrophils during APAP 
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overdose to further confirm that neutrophils do not participate in exacerbation of injury.  
Interestingly, during injury resolution neutrophils become activated especially in 
peripheral blood but did not have enhanced reactive oxygen priming in the liver.  These 
findings were confirmed with NADPH oxidase deficient mice which had no alteration in 
injury resolution.  Interestingly, these data were very similar to neutrophil function in 
human APAP overdose patients. These data indicate that activation of neutrophils might 
be critical for maintaining host defense during hepatic impairment.  As a whole, this 
dissertation shows IL-1β is a minor participant in the sterile inflammatory response 
following APAP overdose, but this response is critical for neutrophil activation and 
eventual injury resolution. 
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1. Introduction 
 
 
 
 
 
 
 
 
 
Portions adapted from: 
Liver International, 32(1):8-20, Acetaminophen hepatotoxicity and repair: the role of 
sterile inflammation and innate immunity, 2012, with permission from Wiley. 
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1.1 History of APAP 
The history of acetaminophen (APAP) dates back to the 1850’s when a French chemist, 
Charles Gerhardt, synthesized and described acetanilide, while APAP itself was first 
described in chemical literature in 1878.  Around this time another drug, phenacetin, 
was also discovered.  In 1886 acetanilide was inadvertently used in the clinic by the 
French doctors Arnold Cahn and Paul Hepp, who noticed that in addition to its 
antipyretic (fever reducing) properties it was also an analgesic (pain reducer).  In 1899 it 
was demonstrated by the German chemist Karl Morner that acetanilide could be 
converted via hydroxylation to form APAP.  For much of the first half of the 20th century 
these drugs were limited in usage due to fears of methemoglobinemia. 
In the 1940s Julius Axelrod working in the laboratory of Bernard B. Brodie at the 
National Institutes of Health discovered that the active metabolite of both acetanilide 
and phenacetin is actually APAP.  This discovery essentially ended the use of 
acetanilide and it was determined the methemoglobinemia induced by acetanilide is due 
to small percentage of the drug being converted to aniline.  Phenacetin was still used 
clinically until the 1980s as a preparation of aspirin-phenacetin-caffeine (APC).  A large 
percentage of phenacetin was converted to APAP through first pass metabolism 
however the parent drug also had pharmacologic actions.  It was subsequently 
determined that phenacetin caused an increased risk of kidney injury and it was 
suspected as a carcinogen and therefore was subsequently removed from the market.  
The findings of Axelrod and Brodie demonstrated that APAP is the dominant active 
pharmacologic compound and spurred its use clinically. 
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In 1951 the Institute for the Study of Analgesic and Sedative Drugs held a symposium in 
New York City regarding the efficacy of APAP.  It was reported at this symposium that 
APAP was equally efficacious as aspirin for pain relief and fever reduction without the 
adverse side effects like gastrointestinal bleeding, stomach irritation and alterations in 
blood coagulation.  This prompted McNeil Laboratories (now McNeil Consumer Health, 
a Johnson & Johnson company) to begin research and potential marketing of the drug.  
Two years later McNeil marketed the prescription elixir named Algoson which was a 
formulation of butabarbital and APAP. 
Then in 1955 McNeil released a children’s elixir named Tylenol (N-aceTYL-p-
aminophENOL) and in 1961 the adult formulation was marketed.  These events gave 
rise to one of the most widely used and economically successful drugs ever produced. 
However, like with all drugs there is good and bad, and the story is not free from 
controversy. 
 
1.2 Background of APAP 
It is estimated that each week approximately 50 million Americans consume 
acetaminophen either alone in combination formulations. APAP can be used by itself in 
oral (tablet, capsule, caplet, liquid), rectal and intravenous formulations. It is found in 
numerous over the counter formulations like cold, flu and allergy combinations.  
Additionally, it is present in many prescription formulations that include controlled 
substances like Lortab®, Darvocet®, Vicodin®, Percocet® and many others. If taken at 
therapeutic doses APAP is very safe with few side effects, however overdose of APAP 
is currently the most frequent cause of acute liver failure in the US, the UK and many 
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other countries and accounts for nearly one half of all acute liver failure cases (Larson 
et al., 2005).  The therapeutic dose of APAP for an adult is 4g per day (~60mg/kg/day); 
a serious risk of potentially fatal overdose can occur at approximately five times that 
dose (300mg/kg/day) and even 2.5-3 times a therapeutic dose can have toxic 
consequences. Cases of APAP overdose occur intentionally (suicide attempt) and 
unintentionally, with an increasing number of cases of unintentional overdosing due to 
the consumption of multiple drug preparations containing APAP.   
Seminal work in the mechanism of APAP toxicity was performed in the early 1970’s 
(Mitchell et al., 1973a,b; Jollow et al., 1973). These studies demonstrated that APAP 
hepatotoxicity involves the formation of a reactive metabolite, hepatic glutathione (GSH) 
depletion, and protein binding, all of which correlate with liver injury (Mitchell et al., 
1973a,b; Jollow et al., 1973).  
Although the focus of research in understanding the mechanisms of APAP-induced liver 
injury was always on intracellular events in hepatocytes, there is an increasing 
awareness that nonparenchymal cells of the liver and infiltrating inflammatory cells may 
be involved in the pathogenesis (Jaeschke 2005; Liu and Kaplowitz 2005). However, in 
contrast to the widely accepted contribution of inflammatory cells in the pathophysiology 
of hepatic ischemia-reperfusion injury, obstructive cholestasis and endotoxemia 
(Jaeschke 2003; Jaeschke 2006; Jaeschke and Hasegawa 2006), the contribution of 
inflammation in the mechanism of APAP-induced liver injury is highly controversial 
(Jaeschke 2008). The objective of these studies was to determine if the formation of IL-
1β is a critical event in toxicity and if the production of IL-1β modulates neutrophil 
activity and function.  Additionally we functionally characterized the role of neutrophils in 
5 
 
the pathophysiology of APAP overdose to determine their role in injury as well as injury 
resolution and tissue repair.  
 
1.3 APAP compared to other drug induced liver toxicities 
Adverse drug reactions can be divided into five categories.  Type A (augmented) 
adverse reactions represent an exaggeration of pharmacologic effect; an example of 
this is excessive bleeding due to anticoagulant overdose.  Type B (bizarre or 
idiosyncratic) reactions are not predictable based on dose, exposure and 
pharmacology; examples include troglitazone, flucloxacillin and other drugs that cause 
idiosyncratic drug-induced liver injury (IDILI).  Type C (chemical) reactions have 
predictable toxicity based on the chemical structure of the parent drug or metabolite; 
APAP is the classical example of a chemical adverse reaction which was demonstrated 
by the four part series of Mitchell and coworkers in 1973.  Type D (delayed) adverse 
reactions are normally a secondary effect of a previous drug treatment; a typical 
example would be a secondary cancer following chemotherapy.  Type E (End-of-
treatment) reactions occur upon removal of drug; an example would be the induction of 
seizure upon stoppage of phenytoin. 
Drug disposition alone cannot explain the other causes of drug induced liver injury 
(DILI) because there is no association with the accumulation of excess drug or 
metabolite that would result in concentrations that are toxic to the liver (Kaplowitz, 
2005). This is in contrast to what is seen in APAP overdose.  Excessive concentration 
and hepatocytes-specific reactive metabolite generation result in this injury.  The causes 
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of the other DILI are largely unknown but there are several theories to the mechanisms 
which include hapten formation, immune-mediated cell death, and mitochondrial stress. 
In most cases IDILI is regarded as dose-independent, however this is most likely an 
incorrect statement.  IDILI is very rarely seen at doses of <10mg/day and more than 
three fourth of IDILI cases occur when the drug is given at >50mg/day (Zhang et al., 
2011).  The notion that IDILI is dose independent probably arises from the fact that the 
overwhelming majority of patients taking the drug are non-responders in regard to 
toxicity (Uetrecht, 2007). 
Drugs with the highest IDILI concern are antineoplastic agents, NSAIDs, antivirals, 
antidepressants, and antimicrobials, and in the US, antimicrobials account for 46% of 
IDILI (Fontana et al., 2010).  In a majority of cases (73%) a single prescription was 
implicated as the cause of IDILI (Chalasani et al., 2010).  Clinically, the only effective 
treatment for DILI is to stop the administration of the drug and offer supportive care.  
The clear exception to this rule is the administration of N-acetylcysteine for APAP 
overdose (and potentially carnitine for valproic acid overdose). 
There are several reasons to assume IDILI is immune mediated.  The most striking is 
the time to onset; depending on the drug it could take months to over one year prior to 
initiation of IDILI which would indicate an adaptive immune response.  Additionally 
elevated transaminase activities can be observed with some drugs up to one month 
following discontinuation of drug (Uetrecht, 2007). Some IDILI also involves the 
generation of antidrug antibodies or autoantibodies (Uetrecht, 2007).  The very rapid 
onset to APAP-induced liver injury is in stark contrast to other drug-induced liver injury; 
additionally no biologically relevant clinical manifestations occur with APAP unless it is 
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taken at supra-therapeutic levels (occasionally transient ALT increases can be seen at 
therapeutic levels).  Patients who overdosed on APAP have no additional increased 
probability of subsequent liver injury (autoantibodies or antidrug antibodies) and in fact 
the liver repairs completely without risk of fibrosis or cirrhosis. 
 
1.4 Clinical implication and treatment of APAP overdose 
APAP hepatotoxicity is initiated by the P450-mediated metabolic conversion to N-acetyl-
p-benzoquinone imine (NAPQI) which is discussed in more detail (1.6.1 and 1.8).  It has 
been recognized clinically since the 1960s (Thomas et al., 1966) as cause of severe 
liver injury which can ultimately lead to death.  APAP overdose in the US results in 
~50,000 emergency room visits, ~25,000 hospital admissions and ~500 deaths annually 
(Larson et al., 2005).  After overdose, elevations in serum liver enzymes, alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST), can be seen within one 
day and generally peak around three days post overdose.  This loss of hepatocyte mass 
prevents normal hepatic function like the production of serum proteins (coagulation 
factors, complement components, albumin and others) and the removal of endo- and 
xenobiotics.  Impaired liver function can be monitored clinically by blood coagulopathies 
(increased international normalized ratio (INR)) and elevation in serum bilirubin.  Upon 
liver recovery these laboratory results will begin to normalize, however if the liver mass 
is insufficient these lab results will continue to worsen.  
The administration of N-acetylcysteine (NAC) was shown to be an effective antidote 
against APAP hepatotoxicity in clinical practice (Prescott et al., 1977) and still today is 
the only approved drug to treat APAP overdose patients (Polson et al., 2005).  
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Treatment involves the administration of NAC intravenously (i.v.) or orally.  The i.v. 
regimen involves 150mg/kg/h over 1 h followed by 12.5mg/kg/h over 4 hours then 
6.25mg/kg/h over 3 days.  Oral dosing of NAC begins with a loading dose of 140mg/kg 
and 70mg/kg every four hours.  Duration of treatment depends on clinically determined 
need but generally lasts a minimum of 3-5 days.  The decision to treat patients with 
NAC generally occurs very quickly because timing is critical for patient outcome, so if 
very high serum transaminases are observed or the patient claims to have take large 
quantities of APAP NAC will started immediately.    To aid in the decision making 
process, clinicians generally refer to the Rumack-Mathews nonogram.  This is a plot of 
serum APAP concentration versus time post APAP-ingestion.  High APAP concentration 
at a time many hours past ingestion is dangerous and will definitely initiate NAC 
treatment. 
After overdose, in addition to NAC, patients receive supportive care like initial volume 
replacement therapy which reduces lactic acidosis and some patients may eventually 
need to be on renal supportive therapy.  Renal dialysis can also help to reduce 
ammonia which is a very severe problem clinically.  There are reports of renal toxicity 
due to APAP however many believe this toxicity may be mediated by the loss of liver 
function and altered metabolic state of the patient.  Others feel that the expression of 
P450 enzymes in tubule cells are the cause of this injury as evidenced by renal GSH 
depletion (Mudge et al., 1978).  Realistically the major clinical problem in these patients 
is the failing hepatic function and kidney injury is only a secondary problem.  In addition 
patients that recover from the hepatic injury never sustain permanent renal damage.  
Excessive ammonia results in encephalopathy and coma.  If these treatments fail then 
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the only remaining option is liver transplantation which is determined by using the King’s 
College Criteria.  These criteria include INR, serum creatinine and encephalopathic 
grade; additionally, clinicians today use low arterial pH as another criterion.  These 
patients are also at high risk of the development of infection or sepsis due to prolonged 
stay in the hospital and compromised immunity. 
 
1.5 Epidemiology of APAP overdose 
In the largest and most comprehensive retrospective study performed to date, which 
spanned from1998 to 2007, it was reported that of all causes of acute liver failure (ALF), 
APAP was the predominant cause (46%) and liver injury from all other drugs accounted 
for 11% (Lee et al., 2008).  Additionally, the spontaneous patient survival is quite 
different between etiologies; APAP showed a 65% spontaneous survival rate while the 
spontaneous survival rate from other drugs was only 29% (Lee et al., 2008).  APAP 
overdose has a sex bias with approximately three-fourths of the patient being female 
(Lee et al., 2008); other forms of DILI also show a female predominance but not any 
other cause of ALF (Lee et al., 2008).  Most emergency departments reporting APAP 
overdose show no difference in distribution of intentional versus unintentional overdose 
(Lee et al., 2008).  Additionally, in these patients who overdosed there is no difference 
in quantity taken (average of 20-25 grams), maximum ALT, spontaneous survival, 
percentage of patients who underwent liver transplantation, or patients that died (Lee et 
al., 2008).  
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1.6 APAP pharmacokinetic (PK) and pharmacodynamics (PD) 
The PD of APAP makes for a very interesting story.  The mechanism of action of APAP 
for its pharmacologic activity in vivo is almost completely unknown.  It is believed to act 
centrally for both its analgesic and antipyretic effects.  It differs in mechanism from the 
commonly used NSAIDs and aspirin because it will not inhibit cyclooxygenases (COX) 
in the periphery, however it was reported that APAP inhibits COX-2 centrally by 
reducing the heme at the peroxidase domain rather than inhibiting the catalytic domain 
(Kis et al., 2005).  Additionally, it is believed that APAP cannot act as an anti-
inflammatory because of high peroxide levels in inflamed tissue (Kam and So, 2009).  It 
was initially believed that APAP inhibited the previously undiscovered COX-3.  In 2002, 
an alternative splicing variant of canine Cox-1 was discovered and named Cox-3 
(Chandrasekharan et al., 2002); it was thought to answer the long sought after question 
of the APAP therapeutic target.  The problem was a frameshift in rodents and humans 
prevented all activity of the COX-3 enzyme (Kis et al., 2005).  Since this time, the COX-
3 hypothesis has fallen out of favor.  Most recently a group has reported that the 
mechanism of action might be the reactive metabolites acting centrally to reduce 
voltage-gated calcium and sodium currents in primary sensory neurons (Andersson et 
al., 2011). All mechanisms of therapeutic action to date are still speculative and highly 
scrutinized. 
APAP has a relatively high pKa (9.5) therefore it does not ionize in compartments in 
vivo.  Additionally being a small molecule (molecular weight: 151.2 Da) it is freely 
diffusible across cell membranes; this gives credence to its ability to act centrally. To be 
popular as an analgesic and antipyretic APAP should demonstrate an effect quickly and 
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generally it is regarded to have an onset of action within 30 minutes of oral dosing which 
should last between 4-6 hours (which also happens to be the dosing regimen).  The 
half-life of APAP in humans ranges between 60 to 180 minutes with a normal half-life of 
approximately 90 minutes (Koch-Weser, 1976).  In neonates and overdose patients the 
half-life is longer (2 to 5 hours) presumably due to poor glucuronidation or general liver 
impairment, respectively (Koch-Weser, 1976).  Peak serum APAP concentrations in 
humans occurs as quickly as 10 minutes post ingestion but can occur in some people 
up to 1 hour post dosing and are generally around 30 μg/mL (~200 μmol/L).  Since 
APAP is a small drug the excretion occurs mainly through the kidney, with 2-5% being 
eliminated as the parent drug, ~55% as the glucuronide metabolite (on the hydroxyl 
group), ~30% as the sulfate metabolite (on the hydroxyl group) and the remaining dose 
as mercapturic acid (GSH conjugated to APAP at the meta position).  This is shown in 
1.6.1. 
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1.6.1 
 
Most of the ingested dose of APAP is conjugated by glucuronidation (~55-60%) or 
sulfation (~25-30%) and eliminated.  The remaining APAP is converted to the 
quinoneimine (NAPQI).  This electrophilic metabolite is detoxified by GSH and 
eliminated as mercapturic acid in the urine.  If this detoxification pathway is 
overwhelmed adduction of cellular proteins can occur thereby initiating toxicity. 
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1.7 Animal models of APAP overdose 
As with most drugs and toxicants, the most commonly used animal models are rodent 
models with rats and mice being the most common.  Interestingly these two models are 
quite different in terms of toxicity and potentially mechanism of injury.  Rats are resistant 
to APAP induced liver injury, but the reason for this insensitivity is unclear.  Mice on the 
other hand present a liver injury similar to what is observed clinically in humans.  The 
progression of injury is more rapid in mice than humans with liver enzymes peaking 12-
24h post overdose rather than 1-2 days which is seen in patients.  For this reason and 
the use of gene knockout animals, mice are the most commonly used model species for 
mechanistic studies.  Other animal models have also been used but are not commonly 
studied.  APAP in both dogs and pigs results in severe liver injury however many of 
these studies are highly variable in terms of liver injury and are not commonly used as 
models (Gazzard et al., 1975; Thompson et al., 1972).  Cats are a poor model of APAP 
overdose because they are inefficient glucuronidators (Welch et al., 1966); in fact a very 
small amount of APAP is highly toxic in cats and can cause methemoglobemia 
independent of liver injury (Welch et al., 1966). Many of these studies in larger animals 
(dogs and pigs) also report the development of methemoglobinemia which would make 
them poor models for human APAP overdose because this does not occur clinically 
(Gazzard et al., 1975; Thompson et al., 1972).    
 
1.8 Intracellular mechanisms of APAP toxicity 
Initiation Phase: APAP-induced liver injury depends on the metabolism of a small 
fraction of the overall dose of APAP (generally <10%) through the cytochrome P450 
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system (CYP) (Mitchell et al., 1973a). The most predominant isoform catalyzing this 
reaction is CYP2E1, however CYP1A2, CYP2D6 and potentially others form the 
reactive metabolite, N-acetyl-p-benzoquinone imine (NAPQI).  Detoxification of NAPQI 
with GSH occurs either spontaneously or is catalyzed by glutathione-S-transferases 
(Dahlin et al., 1984). If the formation of NAPQI exceeds the capacity of GSH to 
eliminate this metabolite, NAPQI can react with protein sulfhydryl groups, which leads to 
the formation of protein adducts (Mitchell et al., 1973b; Jollow et al., 1973). Initially, it 
was assumed that covalent binding of APAP to proteins was the cause of cell death 
(Mitchell et at., 1973a,b; Jallow et al., 1973). Although cell death correlates with early 
protein binding (Roberts et al., 1991), it was obvious that the total amount of adducts is 
limited and may be insufficient to cause cell death. Therefore it was hypothesized that 
NAPQI may selectively affect vital proteins within the cell. A substantial number of 
adducted proteins were identified (Cohen et al., 1997; Qiu et al., 1998), however none 
of the proteins adducted were so critical that a moderate loss of enzyme activity would 
account for the rapid cell death. Studies of the non-hepatotoxic regioisomer of APAP, 3'-
hydroxyacetanilide (AMAP) suggested that binding of mitochondrial proteins was 
essential for toxicity (Qiu et al., 2001; Tirmenstein et al., 1989). The parallel recognition 
that APAP overdose can inhibit mitochondrial respiration (Meyers et al., 1988; Ramsay 
et al.; 1989) and causes a selective mitochondrial oxidant stress (Jaeschke 1990) led to 
the concept that early protein binding is the initiator of toxicity, which requires 
amplification and propagation in order to cause cell death (Jaeschke et al., 2003; 
Jaeschke and Bajt 2006).  
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Propagation Phase. Central to amplifying the initial stress of protein adduct formation 
are the mitochondria. Although some of the mechanistic details are still unknown, it is 
well established that the mitochondrial translocation of bax is a very early event 
(Jaeschke and Bajt 2006; Bajt et al., 2008; Bajt et al., 2006). Bax together with Bak form 
pores in the outer mitochondrial membrane that lead to the release of intermembrane 
proteins including cytochrome c, the second mitochondrial activator of caspases (smac), 
endonuclease G and apoptosis-inducing factor (AIF) (Bajt et al., 2008). Endonuclease G 
and AIF translocate to the nucleus (Bajt et al., 2006) and contribute to the characteristic 
nuclear DNA fragmentation and cell death (Bajt et al., 2008). Independent of bax, the 
mitochondrial protein binding causes inhibition of mitochondrial respiration resulting in 
oxidant stress and peroxynitrite formation in mitochondria (Knight et al., 2001; Cover et 
al., 2005). The oxidant stress is responsible for mitochondrial DNA damage (Cover et 
al., 2005) and the opening of the mitochondrial membrane permeability transition pore 
(MPT) (Masubuchi et al., 2005; Kon et al., 2004; Ramachandran et al., 2011), which 
triggers the collapse of the membrane potential and loss of ATP formation. The resulting 
mitochondrial swelling leads to the rupture of the outer membrane with release of 
intermembrane proteins and subsequent nuclear DNA fragmentation (Bajt et al., 2008). 
The selective scavenging of mitochondrial peroxynitrite by accelerating the recovery of 
mitochondrial GSH levels documented the critical role of peroxynitrite in the 
pathophysiology (Knight el al., 2002; Bajt et al., 2003). In addition, the supply of large 
doses of N-acetylcysteine and GSH supports mitochondrial function by providing 
substrates for ATP synthesis (Saito et al., 2010). Together the emerging evidence is 
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very strong that dysfunction of mitochondria and the resulting energy crisis and nuclear 
DNA damage are key events in causing oncotic necrotic cell death (Gujral et al., 2002). 
 
1.9 Sterile inflammation, cytokine formation and inflammasome activation  
A fundamental principle of sterile inflammation is the requirement for necrotic cell death 
to trigger this inflammation (Scaffidi et al., 2002). Thus, some initial hepatocellular injury 
must occur to initiate the inflammatory response which may then modulate the injury.  
Following APAP-induced toxic insult the formation of cytokines such as TNF-α, IL-1β 
and others, has been well described (Blazka et al., 1995; Lawson et al., 2000; Gardner 
et al., 2003; James et al., 2005) but the initiating mechanisms emerged only recently. 
Damage associated molecular patterns (DAMPs) are molecules released from dying 
cells that are ligands for toll-like receptors (TLRs) on macrophages and other cell types 
(Schwabe et al., 2006; Jeannin et al., 2008). DAMPs identified to be released during 
APAP hepatotoxicity include high mobility group box 1 protein (HMGB1), heat shock 
proteins, mitochondrial and nuclear DNA fragments and others (Jaeschke 2008; Jahr et 
al., 2001; Martin-Murphy et al., 2010; Antoine et al., 2009). A hypoacetylated form of 
HMGB1 can be passively released by necrotic cells (Antoine et al., 2009) and a 
hyperacetylated form of HMGB1 is secreted by activated macrophages and indicates an 
inflammatory response (Bonaldi et al., 2003). Both hyper- and hypo-acetylated forms of 
HMGB1 are found in plasma after APAP overdose (Antoine et al., 2009). However, it 
appears that HMGB1 alone is less effective as a pro-inflammatory mediator; 
combinations of HMGB1 with other DAMPS such as DNA fragments are the most 
potent inflammagens (Bianchi 2009). Although these DAMPs are clearly released into 
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the plasma during APAP-induced liver injury, the impact on the injury mechanisms is 
controversial. Antibodies against HMGB1 have been shown to reduce hepatic neutrophil 
accumulation without effect on injury (Jaeschke 2008). However, other authors reported 
a minor reduction in liver injury (Antoine et al., 2010) or drastically reduced liver injury in 
the presence of HMGB1 antibodies (Chen et al., 2009). In addition, HMGB1 antibodies 
attenuated cytokine and chemokine (TNF-α, MCP-1, IL-6) formation (Antoine et al., 
2009; Chen et al., 2009) supporting the hypothesis that HMGB1 is an important 
mediator of the inflammatory response after APAP overdose. Mice deficient in TLR4, a 
receptor for HMGB1, showed a moderate reduction in APAP-induced injury (Yohe et al., 
2006) but mice deficient in TNF-α (Boess et al., 1998) were not protected. In contrast, 
TNF receptor 1 (TNFR1)-deficient mice had exaggerated liver injury, which correlated 
with accelerated iNOS induction and peroxynitrite formation (Chiu et al., 2003).  
DNA fragmentation is a characteristic feature of APAP-induced cell death (Cover et al., 
2005; Ray et al., 1990; Lawson et al., 1999). DNA fragments released during APAP-
induced necrosis (Jahr et al., 2001; McGill et al., 2012) can be recognized by TLR9 
(Imaeda et al., 2009). The pathophysiological relevance of TLR9 has been implicated by 
the protective effect of TLR9 antagonists and in TLR9-deficient mice (Imaeda et al., 
2009). TLR9 stimulation can activate cytokine formation through activation of NF-κB 
(Imaeda et al., 2009). It was hypothesized that interleukin-1α and IL-1β are critical 
mediators of APAP hepatotoxicity based on the observation that IL-1 receptor-deficient 
(IL-1R1-/-) mice are protected (Chen et al., 2007) and the reports that mice deficient in 
components of the Nalp3 inflammasome show substantially reduced injury (Imaeda et 
al., 2009). This protein complex consists of Nalp3 (NACHT, LRR, and pyrin domain-
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containing protein 3), ASC (apoptosis-associated speck-like protein containing a 
CARD), and caspase-1 (Lamkanfi et al., 2009). Based on the reduced injury in Nalp3-/-, 
ASC-/- and caspase-1-/- mice, it was concluded that processing of pro-IL-1β and pro-IL-
18 to the active, soluble cytokines is critical for APAP-induced liver injury (Imaeda et al., 
2009). The IL-1 receptor 1 (IL-1R1) and TLRs share a common signaling domain called 
the Toll-like/IL-1 Receptor (TIR) domain on the cytoplasmic side of the cell surface 
receptor as well as additional adapter molecules all of which contain additional TIR 
domains (O’Neill and Bowie, 2008; Kenny and O’Neill, 2008).  The lack of a cytoplasmic 
death domain in the IL-1R makes it impossible for IL-1α or β to directly induce cell death 
(Sims et al., 2010) therefore this toxicity would be mediated through inflammatory cell 
activation and recruitment.  
Taken together, there is established release of various DAMPs after APAP overdose 
triggering the formation of a number of cytokines and chemokines and initiating 
recruitment of neutrophils and monocytes into the liver. However, there is no convincing 
evidence to suggest that the pro-inflammatory mediator formation results in direct cell 
death (apoptosis) (Gujral et al., 2002) or a neutrophil- or macrophage-mediated injury 
(Jaeschke 2008). In contrast, inflammatory cytokines are able to modulate intracellular 
events within hepatocytes thereby altering toxicity.   
 
1.10 Role of Kupffer cells in APAP hepatotoxicity 
The resident macrophages of the liver (Kupffer cells) are activated within 1-2 h after 
APAP overdose in mice as indicated by the formation of cytokines (Blazka et al., 1995; 
Lawson et al., 2000; Gardner et al., 2003; James et al., 2005; Martin-Murphy et al., 
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2010; Ito et al., 2003). In this respect it is important to recognize that the first report on 
macrophage activation after APAP used a rat model (Laskin et al., 1986).  The rat is a 
poor model for APAP overdose because the rat is highly resistant to toxicity, whereas 
the mouse model more closely mimics human APAP overdose (as described in 1.7). A 
similar investigation using GdCl3 was later repeated in the mouse (Michael et al., 1999). 
In this report, GdCl3 completely eliminated the oxidant stress and peroxynitrite formation 
and liver injury during the first 8 h after APAP (Michael et al., 1999). In this case, GdCl3 
clearly acted on Kupffer cells as infiltrating monocytes are not detectable before 12-24 h 
in the mouse (Holt et al., 2008). However, the main conclusion of this manuscript, i.e. 
that Kupffer cell-derived oxidants are responsible for the centrilobular injury (Michael et 
al., 1999), is highly questionable. First, the most active Kupffer cells in terms of reactive 
oxygen formation are located in the periportal area as part of the vital host defense 
function (Bautista et al., 1990; Jaeschke et al., 1991). Thus, it is unlikely that oxidants 
formed in the periportal area cause selectively damage to centrilobular hepatocytes. 
Second, mice with a genetic deficiency of a functional NADPH oxidase, the enzyme by 
which phagocytes such as Kupffer cells produce reactive oxygen, do not show reduced 
oxidant stress or peroxynitrite formation and liver injury after APAP overdose (James et 
al., 2003). Likewise, inhibitors of NADPH oxidase do not protect against APAP 
hepatotoxicity (Cover et al., 2006). Thus, it is highly unlikely that Kupffer cells are 
involved in the pathophysiology of APAP-induced liver injury by directly causing cell 
injury through reactive oxygen and peroxynitrite formation. In support of these findings, 
several subsequent studies using GdCl3 found either very little or even no protection (Ito 
et al., 2003; Knight et al., 2004; Ju et al., 2002). Even the sinusoidal endothelial cell 
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injury and hemorrhage that occurs early after APAP overdose in certain mouse strains 
appears to be related to APAP toxicity in SEC rather than indirect cytotoxicity of Kupffer 
cells (Knight et al., 2001; Lawson et al., 2000; Ito et al., 2003; Ju et al., 2002; Yin et al., 
2010). However, the most important finding related to Kupffer cells was reported by Ju 
et al (Ju et al., 2002). This study demonstrated that elimination of Kupffer cells by 
clodronate liposomes actually increased APAP toxicity. The most likely explanation is 
related to the elimination of the formation of IL-10, IL-6 and other cytokines and of 
cyclooxygenase products (Ju et al., 2002). IL-10 was shown to protect against APAP 
toxicity by downregulation of iNOS expression and peroxynitrite formation (Bourdi et al., 
2002). In addition, cyclooxygenase products induce heat shock proteins (Reilly et al., 
2001), which protect against APAP toxicity (Tolson et al., 2006). Together, these data 
demonstrate that the dominant effect of Kupffer cell activation after APAP is not to 
cause cytotoxicity by oxidant formation but to limit toxicity by preventing excessive iNOS 
induction, by promoting cytoprotective gene expression and by supporting regeneration.  
 
1.11 Role of NK and NKT cells in APAP hepatotoxicity 
It was reported that depletion of natural killer (NK) and NK T cells in the liver exerted a 
protective effect against APAP hepatotoxicity (Liu et al., 2004). The increase in a large 
number of cytokines and chemokines including interferon-γ (IFN-γ) after APAP 
treatment was substantially reduced in NK and NKT cell-depleted mice (Liu et al., 
2004). In addition, down-regulation of the Fas receptor and reduced neutrophil 
accumulation in the NK/NKT cell-depleted mice was observed. Interestingly, the effect 
of APAP on cytokine and chemokine formation, Fas receptor expression and neutrophil 
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infiltration could also be reproduced in IFN-γ-deficient mice (Ishida et al., 2002). 
Because IFN-γ formation was mainly attributed to NK and NKT cells, it was concluded 
that these cell types are responsible for IFN-γ production and the more severe injury 
after APAP overdose (Liu et al., 2004). It was later determined that the presence of 
DMSO as a solvent in these studies activated NK and NKT cells which does not occur 
without DMSO (Masson et al., 2008). In all, it was found that DMSO used in these initial 
studies increased activation of these NK and NKT cells and in particular enhanced 
granzyme B and IFN-γ production. Depletion of NK and NKT cells does not alter APAP-
induced injury unless these cell types are pre-activated with DMSO (Masson et al., 
2008). Despite the limitations, the initial study did demonstrate that IFN-γ has the 
potential to modulate APAP-induced toxicity, even if it was induced under non-
physiological conditions. Further confirming the potential of IFN-γ to alter APAP toxicity, 
IFN-γ-/- mice and wild-type mice treated with IFN-γ neutralizing antibody were used 
(Ishida et al., 2002). Depending on the time after APAP overdose IFN-γ-/- mice showed 
a 2- to 8-fold reduction in plasma ALT activities and the neutralizing antibody reduced 
ALT levels approximately 3-fold at 24 hours.  The reduction in injury also correlated with 
reduced immune cell infiltration, cytokine and chemokine formation and liver Fas 
receptor expression (Ishida et al., 2002). 
During APAP-induced sterile inflammation various immune cells are recruited into the 
liver many of which highly express Fas ligand (FasL), and it is well established that 
hepatocytes express Fas receptor. Increased circulating levels of Fas have been 
observed after APAP overdose in humans (Tagami et al., 2003). The Fas/FasL 
interaction has the potential to modulate APAP-induced injury by affecting intracellular 
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signaling mechanisms. Although the easiest interaction between FasL and the Fas 
receptor would be to trigger apoptosis, there is no evidence that apoptotic cell death 
makes a relevant contribution to the overall liver injury after APAP overdose (Williams et 
al., 2011). Nevertheless, several lines of evidence exist linking the Fas receptor and/or 
FasL to altered APAP toxicity. An in vivo study in mice showed that knocking-down the 
Fas receptor protected against 300 mg/kg APAP overdose but the protection was lost 
when the dose was increased to 700 mg/kg (Zhang et al., 2000). These experiments 
utilized antisense or scrambled oligonucleotides, which were injected once per day for 
four days prior to APAP overdose. In this study potential alterations in APAP 
metabolism and/or GSH levels were not evaluated (Zhang et al., 2000). This raises the 
possibility that the protection may have been an indirect effect. A different study 
demonstrated that subliminal activation of Fas by the Fas-activating antibody, Jo-2, 
enhanced APAP-induced injury (Tinel et al., 2004). In these experiments, the very low 
dose of Jo-2 itself caused no plasma ALT increase or any detectable caspase activation 
in the liver. If administered prior to APAP, however, Jo-2 caused a more than two-fold 
increase in APAP induced injury (Tinel et al., 2004). In this study it was shown that the 
subliminal Fas activation increased iNOS induction, which then enhanced APAP-
induced injury (Tinel et al., 2004) linking Fas receptor activation to a critical intracellular 
signaling event. Thus, three independent studies demonstrated three unique ways that 
Fas receptor activation and cytokine formation can modulate APAP toxicity. Potential 
Fas activation mediated through infiltrating leukocytes (ie. NK and NKT cells) alters 
intracellular signaling within the hepatocyte to make them more vulnerable to APAP-
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induced toxicity by a mechanism independent of the Fas/FasL apoptotic cell death 
pathway. 
 
1.12 Role of neutrophils in APAP hepatotoxicity 
The early release of DAMPs and formation of cytokines during the sterile inflammatory 
response after APAP overdose leads to recruitment of neutrophils into the hepatic 
vasculature (Scaffidi et al., 2002; Lawson et al., 2000). As has been demonstrated in a 
number of cases, given the appropriate chemotactic signal from the parenchyma, these 
leukocytes can extravasate and seriously increase liver injury (Jaeschke 2003; 
Jaeschke 2006; Jaeschke and Hasegawa 2006). Despite the initial results arguing 
against an active role of neutrophils in APAP hepatotoxicity (Scaffidi et al., 2002; 
Lawson et al., 2000), two studies using the identical experimental approach suggested 
that neutrophils are responsible in part for APAP-induced liver injury (Liu et al., 2006; 
Ishida et al., 2006). This conclusion was mainly based on the use of a neutropenia-
inducing antibody, which was injected 24 h before APAP (Liu et al., 2006; Ishida et al., 
2006). However, when animals were treated with the same antibody after APAP 
administration, but still before the onset of injury, neutropenia did not protect (Cover et 
al., 2006). The reason for these contradicting results using the same reagent was that 
the pretreatment regimen caused not only neutrophil depletion but also triggered a 
preconditioning effect due to the accumulation of the antibody-tagged neutrophils in the 
liver and the attempts of Kupffer cells to remove them (Bautista et al., 1994; Jaeschke 
and Liu 2007). Phagocytosis of inactivated neutrophils causes Kupffer cell activation 
(Bautista et al., 1994) and triggers a stress response in hepatocytes including induction 
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of inflammatory genes and a number of protective genes, e.g. metallothionein, heme 
oxygenase -1 and others (Jaeschke and Liu 2007). Consequently, hepatocytes from 
animals pretreated with this neutropenia antibody were more resistant to APAP toxicity 
independently of the lack of neutrophils in blood. This conclusion is further supported by 
the lack of protection of mice deficient in ICAM-1 (Cover et al., 2006) and phox91 
(James et al., 2003) as well as the ineffectiveness of pharmacological inhibitors of 
NADPH oxidase (Cover et al., 2006).  
 
1.13 Innate immunity and liver regeneration 
In addition to the injury mechanisms, initiation of regeneration is critical for the repair of 
the damaged liver tissue and the recovery of the patient (Mehendale 2005). Vascular 
endothelial growth factor (VEGF), IL-6, TNF-α and other mediators have been 
implicated in promoting tissue regeneration after APAP overdose (Chiu et al., 2003; 
Croyle et al., 2009; Mehendale 2005; Donahower et al., 2006; Kato et al., 2010; James 
et al., 2003b). Dividing hepatocytes closest to the area of necrosis are replacing the 
dead cells (Bajt et al., 2003). However, a prerequisite of hepatocyte proliferation is the 
removal of necrotic cells by phagocytes. Both neutrophils and monocyte-derived 
macrophages are recruited into the area of necrosis. The infiltrating macrophages (M2) 
are distinct from activated resident macrophages of the liver (M1; Kupffer cells) in terms 
of their cytokine profile produced (Laskin et al., 2009; Adams et al., 2010). M2 
macrophages generate IL-10 and other cytokines that down-regulate inflammation and 
promote tissue repair and have a high capacity for phagocytosis (Laskin et al., 2009; 
Adams et al., 2010). M2 macrophages are recruited into the liver within 12-24 h after 
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APAP overdose, i.e. after the peak of injury (Holt et al., 2008). The recruitment of M2 
macrophages specifically into the area of necrosis occurs through formation of 
monocyte chemoattractant protein 1 (MCP-1) generated by injured hepatocytes and 
recruited macrophages (Dambach et al., 2002). Animals deficient in the C-C chemokine 
receptor 2 (CCR2), the receptor for MCP-1 on monocytes, experienced reduced M2 
accumulation during APAP hepatotoxicity and consequently a substantial delay in tissue 
repair (Holt et al., 2008; Dambach et al., 2002). These data support the hypothesis that 
M2 macrophages are critical for the removal of necrotic cells and for tissue repair.  
Prevention of M2 infiltration in CCR2-/- mice led to an increase in hepatic neutrophil 
numbers and delayed clearance of liver neutrophils (Holt et al., 2008). Although the role 
of neutrophils in tissue regeneration has not been specifically investigated, these data 
are not consistent with a vital importance of neutrophils in this process. Clearly, M2 
macrophages appear to be the most critical phagocytes for clearing necrotic cell debris 
and shutting down inflammation.      
 
1.14 Purpose and Aims 
It has been shown that sterile inflammation and the subsequent cytokine production can 
directly modulate the injury after APAP overdose.  Additionally the initial inflammatory 
response also has an impact on liver repair and regeneration after APAP overdose.  
The mechanism of how this occurs is highly debated and there are two main theories.  
Some people believe this sterile inflammation activates immune cells and these immune 
cells come into the liver thereby increasing and amplifying the injury.  The other belief is 
that these cytokines act on hepatocytes or other cells of the liver which alters how the 
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hepatocytes respond to the toxic insult.  This could occur by increasing the expression 
and production of certain proteins that are inherently protective to the hepatocytes.  
Examples include metallothionein, heme oxygenase, heat shock proteins and others.  
Also these inflammatory mediators can act on other cells in the liver like resident 
macrophages.  These cells can produce nitric oxide by the induction of inducible nitric 
oxide synthase (iNOS); this allows for the formation of peroxynitrite with enhances 
mitochondrial injury. 
Numerous cytokines and cytokine signaling pathways have been demonstrated to 
modulate APAP induced injury in the past.  Examples include: IL-10 is protective (Ju et 
al., 2002; Bourdi et al., 2002), IL-13 is protective (Yee et al., 2007), TNF-α is protective 
(Gardner et al., 2003), IP-10 is protective (Bone-Larson et al., 2001), CCR-chemokines 
are protective (Hogaboam et al., 2000), SOCS-3 is protective (Numata et al., 2007), 
IFN-γ increases injury (Liu et al., 2004), and the list continues. 
Several papers (Chen et al., 2007; Imaeda et al., 2009) have implicated that the pro-
inflammatory cytokine, interleukin-1β (IL-1β), is a critical mediator of APAP 
hepatotoxicity and this toxicity occurs predominantly through the recruitment of 
neutrophils.  From what is known about the progression of injury and the subsequent 
inflammatory response following APAP overdose we wanted to evaluate the maturation 
of IL-1β and the role of IL-1β on the progression of liver injury.  Additionally we wanted 
to further characterize the role neutrophils in this process.   
Mature IL-1β is formed by post-translational modification which is dependent on the 
NACHT, LRR, and pyrin domain-containing protein 3 (Nalp3)-inflammasome (Franchi et 
al., 2009). The Nalp3-inflammasome is composed of three proteins including caspase-1 
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(formerly, interleukin-1 converting enzyme), Nalp3 and ASC (apoptosis-associated 
speck-like protein containing a caspase recruiting domain [CARD]) (Franchi et al., 
2009). It has been shown that DAMPs can signal via toll-like receptors (TLRs) and this 
can then activate the inflammasome (Park et al., 2004; Lamkanfi and Dixit, 2009). Upon 
TLR stimulation the Nalp3-inflammasome is assembled and is then capable of 
processing pro-IL-1β to mature IL-1β; only the processed form of IL-1β can be released 
from cells which is then capable of signaling through the IL-1 receptor-1 (IL-1R1) (Sims 
and Smith, 2010).  Both IL-1α and IL-1β signal through IL-1R1.  The actions of these 
cytokines can be attenuated it two ways.  The first is the presence of IL-1R2, which 
lacks the functional intracellular domain for signal transduction and therefore acts as a 
decoy receptor.  The second is the soluble IL-1 receptor antagonist (IL-1ra); it acts as a 
competitive inhibitor for binding of IL-1α and IL-1β to IL-1R1 (Sims and Smith, 2010). 
Previous studies implicating a central role of IL-1β in APAP hepatotoxicity (Chen et al., 
2007; Imaeda et al., 2009) raise some concerns. The most important one is that IL-1 
receptor signaling cannot directly induce cell death due to the absence of a death 
domain (Sims and Smith, 2010). Thus, IL-1β acts mainly as a pro-inflammatory 
mediator activating and recruiting leukocytes, especially neutrophils, into the liver (Bajt 
et al., 2001). However, there is evidence that neutrophils are not involved in the injury 
process after APAP overdose (Lawson et al., 2000; Cover et al., 2006; James et al., 
2003). In addition, pan-caspase inhibitors did not protect during the early injury phase of 
APAP hepatotoxicity (Lawson et al., 1999; Jaeschke et al., 2006). However, it remained 
unclear if these pan-caspase inhibitors can actually affect IL-1β formation and are able 
to reduce liver injury at later time points when neutrophils are more likely to be involved. 
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Many inflammatory mediators are produced during APAP overdose, therefore it was our 
hypothesis that this mediator would have little impact on the progression of injury or 
hepatic neutrophil recruitment, thus, the objective of this investigation was to evaluate 
the potential role of IL-1β in hepatic neutrophil recruitment and progression of liver injury 
after APAP overdose. 
Specific Aim #1: Determine the role of IL-1β on APAP-induced injury 
 If IL-1β is responsible for enhanced injury during acetaminophen overdose then it 
must be produced after overdose, and be present in sufficient concentration for a 
sufficient amount of time to exert a biological effect and subsequently modulate 
injury.  To determine this we evaluated the production and maturation of IL-1β 
during APAP overdose. 
 Mature IL-1β is produced through a caspase-dependent mechanism.  It was 
never evaluated if this occurs during APAP overdose.  Therefore, mice were 
treated with pan-caspase inhibitor to block the maturation of IL-1β during APAP 
overdose.  
 Efficacy of the caspase inhibitor was confirmed by inhibition of caspases in vivo 
by using the galactosamine/endotoxin model of liver injury. 
 Mice with (vehicle) and without (caspase inhibited) mature IL-1β were compared 
after APAP overdose at several time points for liver injury (ALT, necrosis), 
oxidant stress (GSSG formation), neutrophil recruitment, and inflammatory 
mediator production (cytokine/chemokine protein and mRNA). 
 Mice with (wild-type) and without (IL-1R1-/-) functional IL-1-signaling were 
compared after APAP overdose. 
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 Mice were treated with additional, very high doses of recombinant IL-1β after 
APAP to determine if it can enhance injury. 
Specific Aim #2: Determine the role of the Nalp3 Inflammasome on APAP-injury 
 Evaluate APAP induced injury in mice deficient for each component of the Nalp3 
inflammasome versus control and compare liver injury (ALT, necrosis), oxidant 
stress (GSSG formation), neutrophil recruitment, DNA damage and inflammatory 
mediator production (cytokine/chemokine mRNA). 
 Evaluate the release and role of DAMPs (nuclear DNA/histones, hyper- and 
hypo-acetylated HMGB-1, keratin-18) in the injury process in wild-type versus 
Nalp3-deficient mice. 
 Confirm these findings using an inflammasome inhibitor (acetylsalicylic acid) to 
determine injury and inflammation after APAP-overdose. 
Specific Aim #3: Determine if CD18-/- is important in recruitment and activation status of 
neutrophils during the injury phase of APAP-overdose 
 Evaluate the role of neutrophils in the injury progression of APAP overdose in 
control and CD18-deficient mice (these mice are protected in other models of 
neutrophil-mediated liver injury). 
 Compare the quantity and distribution of neutrophils after APAP to bile duct 
ligated mice (which is a known neutrophil mediated injury). 
 Characterize the activation status of neutrophils in the blood and liver (surface 
marker expression and reactive oxygen priming) during the injury phase of APAP 
overdose. 
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 Enhance the activation of neutrophils (through the use of recombinant IL-1β or 
endotoxin) to see if they can exacerbate APAP-induced injury.  
Specific Aim #4: Determine if neutrophils are activated during liver repair 
 Evaluate a time course of APAP induced injury/injury resolution, DNA damage, 
hepatocyte proliferation and neutrophil activation and recruitment.  Aim 3 
evaluated early injury, this evaluates late injury and injury repair. 
 If neutrophils are critical for repair of tissue then activation should be observed.  
To do this we measured liver and blood neutrophils throughout this time course. 
 If NADPH oxidase is critical in these phagocytic cells then impaired recovery 
should be seen in NADPH oxidase deficient mice. 
 Neutrophils may be critical for the recovery from APAP overdose in human 
overdose patients.  To determine this we evaluated activation parameters of 
neutrophils in patients during the injury and injury resolution phases of APAP 
overdose. 
We hypothesized IL-1 signaling would have a very minor role in APAP induced injury. 
We did not expect to see neutrophil activation during the early injury but did expect 
modulation of function later as neutrophils could have an active role in hepatic injury 
resolution or maintenance of peripheral immune function.  To better understand the role 
of neutrophils in the injury and injury resolution process we characterized activation and 
priming status of hepatic and peripheral neutrophils during APAP overdose.   
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Chapter 2 : 
Role of Caspase-1 inhibition and IL-1β formation during APAP overdose 
 
 
 
 
 
 
 
 
 
Reproduced from : 
Toxicology and Applied Pharmacology, 247(3):169-178, Role of caspase-1 and 
interleukin-1beta in acetaminophen-induced hepatic inflammation and liver injury, 2010, 
with permission from Elsevier. 
32 
 
2.1  Abstract 
Acetaminophen (APAP) overdose can result in serious liver injury and potentially death. 
Toxicity is dependent on metabolism of APAP to a reactive metabolite initiating a 
cascade of intracellular events resulting in hepatocellular necrosis. This early injury 
triggers a sterile inflammatory response with formation of cytokines and innate immune 
cell infiltration in the liver. Recently, IL-1β signaling has been implicated in the 
potentiating of APAP-induced liver injury. To test if IL-1β formation through caspase-1 is 
critical for the pathophysiology, C57Bl/6 mice were treated with the pan-caspase 
inhibitor Z-VD-fmk to block the inflammasome-mediated maturation of IL-1β during 
APAP overdose (300 mg/kg APAP). This intervention did not affect IL-1β gene 
transcription but prevented the increase in IL-1β plasma levels. However, APAP-
induced liver injury and neutrophil infiltration was not affected. Similarly, liver injury and 
the hepatic neutrophilic inflammation were not attenuated in IL-1-receptor-1 deficient 
mice compared to wild type animals. To evaluate the potential of IL-1β to increase 
injury, mice were given pharmacological doses of IL-1β after APAP overdose. Despite 
increased systemic activation of neutrophils and recruitment into the liver, there was no 
alteration in injury. We conclude that endogenous IL-1β formation after APAP overdose 
is insufficient to activate and recruit neutrophils into the liver or cause liver injury. Even 
high pharmacological doses of IL-1β, which induce hepatic neutrophil accumulation and 
activation, do not enhance APAP-induced liver injury. Thus, IL-1 signaling is irrelevant 
for APAP hepatotoxicity. The inflammatory cascade is a less important therapeutic 
target than intracellular signaling pathways to attenuate APAP-induced liver injury.   
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2.2  Introduction 
Acetaminophen (APAP) overdose is the most frequent cause of acute liver failure in the 
US and many European countries (Larson et al., 2005). Toxicity is dependent on the 
metabolic activation of APAP to the reactive metabolite N-acetyl-p-benzoquinone imine 
(NAPQI) within hepatocytes (Nelson, 1990) and sinusoidal endothelial cells (Holt et al., 
2010). NAPQI initiates a series of intracellular events critical for hepatotoxicity including 
glutathione depletion and covalent protein modifications leading to mitochondrial 
dysfunction with formation of reactive oxygen species and peroxynitrite (Nelson, 1990; 
Jaeschke and Bajt, 2006; Jaeschke et al., 2003). The oxidant stress is ultimately 
responsible for the opening of the mitochondrial membrane permeability transition 
(MPT) pore (Kon et al., 2004) and necrotic cell death (Gujral et al., 2002). 
APAP-induced liver toxicity is accompanied by an inflammatory response involving 
activation of Kupffer cells and recruitment of neutrophils and mononuclear cells into the 
liver (Jaeschke, 2005; Liu and Kaplowitz, 2006; Laskin, 2009). The inflammatory 
response is initiated by release of cellular contents, some of which can function as 
damage associated molecular patterns (DAMPs) that can directly activate innate 
immune cells (Scaffidi et al., 2002; Martin-Murphy et al., 2010). During this sterile 
inflammation many cytokines and chemokines are up-regulated and innate immune 
cells begin to accumulate in the liver with neutrophils arriving early after the initial 
APAP-induced injury (Lawson et al., 2000). One of these pro-inflammatory cytokines, 
interleukin-1β (IL-1β), has been recently implicated as a critical mediator of APAP 
hepatotoxicity (Chen et al., 2007; Imaeda et al., 2009).   
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Mature IL-1β is formed by post-translational modification which is dependent on the 
NACHT, LRR, and pyrin domain-containing protein 3 (Nalp3)-inflammasome (Franchi et 
al., 2009). The Nalp3-inflammasome is composed of three proteins including caspase-1 
(formerly, interleukin-1 converting enzyme), Nalp3 and ASC (apoptosis-associated 
speck-like protein containing a caspase recruiting domain [CARD]) (Franchi et al., 
2009). It has been shown that DAMPs can signal via toll-like receptors (TLRs) and this 
can then activate the inflammasome (Park et al., 2004; Lamkanfi and Dixit, 2009). Upon 
TLR stimulation the Nalp3-inflammasome is assembled and is then capable of 
processing pro-IL-1β to mature IL-1β; only the processed form of IL-1β can be released 
from cells which is then capable of signaling through the IL-1 receptor-1 (IL-1R1) (Sims 
and Smith, 2010). 
 Previous studies implicating a central role of IL-1β in APAP hepatotoxicity (Chen et al., 
2007; Imaeda et al., 2009) raise some concerns. The most important one is that IL-1 
receptor signaling cannot directly induce cell death due to the absence of a death 
domain (Sims and Smith, 2010). Thus, IL-1β acts mainly as a pro-inflammatory 
mediator activating and recruiting leukocytes, especially neutrophils, into the liver (Bajt 
et al., 2001). However, there is extensive evidence that neutrophils are not involved in 
the injury process after APAP overdose (Lawson et al., 2000; Cover et al., 2006; James 
et al., 2003; Williams et al., 2010). In addition, pan-caspase inhibitors did not protect 
during the early injury phase of APAP hepatotoxicity (Lawson et al., 1999; Jaeschke et 
al., 2006). However, it remained unclear if these pan-caspase inhibitors can actually 
affect IL-1β formation and are able to reduce liver injury at later time points when 
neutrophils are more likely to be involved. Thus, the objective of this investigation was 
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to evaluate the potential role of IL-1β in hepatic neutrophil recruitment and progression 
of liver injury after APAP overdose in a well-established murine model.  
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2.3 Materials and Methods 
2.3.1  
Animals. Eight to twelve week old male C57BL/6J or IL-1 receptor 1 knock-out mice 
(B6.129S7-Il1r1tm1Imx/J), with an average weight of 18 to 22 g were purchased from 
Jackson Laboratory (Bar Harbor, Maine). All animals were housed in an environmentally 
controlled room with 12 h light/dark cycle and allowed free access to food (8604 Teklad 
Rodent, Harlan, Indianapolis, IN) and water. Experimental protocols were approved by 
the Institutional Animal Care and Use Committee of University of Kansas Medical 
Center and followed the criteria of the National Research Council for the care and use 
of laboratory animals in research.  
2.3.2 
Experimental design. All chemicals were purchased from Sigma Chemical Co. (St. 
Louis, MO) unless stated otherwise.  Mice were intraperitoneally injected with 300 
mg/kg APAP (dissolved in warm saline) after overnight fasting, 700 mg/kg D-
galactosamine (Gal) and 100 μg/kg endotoxin (ET), 20 μg/kg recombinant mouse IL-1β 
containing <0.1 ng endotoxin/μg protein (GenScript, Piscataway, NJ), or equivalent 
volumes of saline.  Additionally, some mice were injected (i.p.) with 10 mg/kg Z-VD-fmk 
(EP1013; a generous gift from Dr. S. X. Cai, Epicept Corp., San Diego, CA) (dissolved 
in Tris-buffered saline) two hours after APAP treatment or three hours after Gal/ET. The 
animals were sacrificed 6 or 24 h after APAP or 6 h after Gal/ET. Blood was drawn into 
heparinized syringes for measurement of alanine aminotransferase (ALT) activity 
(Kinetic Test Kit 68-B, Biotron Diagnostics, Inc., Hernet, CA) and cytokine 
concentrations. The liver was removed and was rinsed in ice-cold saline; liver sections 
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were fixed in 10% phosphate buffered formalin for histological analyses. The remaining 
liver lobes were snap-frozen in liquid nitrogen and stored at -80 C.  
2.3.3 
Histology.  Formalin-fixed tissue samples were embedded in paraffin and 5 m sections 
were cut. Sections were stained with hematoxylin and eosin (H&E) for blinded 
evaluation of the areas of necrosis by the pathologist. The percent of necrosis was 
estimated by evaluating the number of microscopic fields with necrosis compared to the 
entire cross section. Additional sections were stained for neutrophils using the anti-
mouse neutrophil allotypic marker antibody (AbD Serotec, Raleigh, NC) as described in 
detail (Williams et al., 2010). Positively stained cells consistent with cellular morphology 
were quantified in 15 high power fields (HPF).  Some sections were also stained for 
terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) in situ cell death 
assay (Roche, Indianapolis, IN) as previously described (Lawson et al. 1999). 
2.3.4 
mRNA expression. Quantification of mRNA expression of several cytokines and 
chemokines was performed by real-time PCR (RT-PCR) analysis as described 
previously (Bajt et al., 2008). cDNA was generated by reverse transcription of total RNA 
by M-MLV reverse transcriptase in the presence of random primers (Invitrogen, 
Carlsbad, CA).  Forward and reverse primers for the genes were designed using Primer 
Express software (Applied Biosystems, Foster City, CA). After normalization of cDNA 
concentration, SYBR green PCR Master Mix (Applied Biosystems) was used for real-
time PCR analysis. The relative differences in expression between groups were 
expressed using cycle time (Ct) values generated by the ABI 7900 instrument (Applied 
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Biosystems).  All genes evaluated were first normalized to β-actin and then expressed 
as a fold increase relative to control which is arbitrarily set as 1.0. Calculations are 
made by assuming one cycle is equivalent to a two-fold difference in copy number 
which is the 2^(-ddCt) formula. 
2.3.5 
Plasma cytokine measurements. Plasma cytokine concentrations were quantified by the 
Bio-Plex bead-based multiplex assay following the kit instructions (Bio-Rad 
Laboratories, Hercules, CA) and analyzed on the Bio-Plex 200 instrument (Bio-Rad).  
2.3.6 
Tissue Caspase-3 Activity. Quantification of hepatic caspase-3 activity was performed 
as previously described in detail (Lawson et al., 1999). Briefly, liver tissue was 
homogenized and protein concentration was normalized after BCA protein assay 
(Thermo Scientific, Rockford, IL). Homogenate was assayed with Acetyl-Asp-Glu-Val-
Asp-7-amino-4-methylcoumarin (Ac-DEVD-AMC) (Enzo Life Sciences, Plymouth 
Meeting, PA) for change in fluorescent intensity over time by fluorometer.  
2.3.7 
Flow Cytometric Analysis of CD11b Expression and Reactive Oxygen Formation: 
CD11b/Gr-1 staining. Neutrophil priming as measured by CD11b expression was 
performed as previously described in detail (Williams et al., 2010). Briefly, heparinized 
whole blood was stained with PE-Cy5-labeled-anti-Gr-1 (BioLegend, San Diego, CA) 
and PE-labeled-anti-CD11b (BioLegend). After red cell lysis samples were analyzed on 
the FACSCalibur (BD, Franklin Lakes, NJ).  
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Reactive Oxygen Species (ROS) Production (Smith and Weideman, 1993; Daley et al., 
2008) Neutrophil ROS priming was performed as previously described in detail 
(Williams et al., 2010). Briefly, whole blood was treated ex vivo for 10 minutes with 
phorbol 12-myristate 13-acetate (PMA) or saline followed by the addition of 
dihydrorhodamine-123 for 10 minutes at 37ºC. Neutrophils were stained with PE-Cy5-
labeled-anti-Gr-1 (BioLegend) then red blood cells were lysed. Samples were analyzed 
on the FACSCalibur and ROS production was evaluated in Gr-1bright neutrophils. 
2.3.8 
Statistics.  All results were expressed as mean  SE. Comparisons between 
multiple groups were performed with one-way ANOVA or, where appropriate, by 
two-way ANOVA, followed by a post hoc Bonferroni test. If the data were not 
normally distributed, we used the Kruskal-Wallis Test (nonparametric ANOVA) 
followed by Dunn’s Multiple Comparisons Test. P < 0.05 was considered significant. 
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2.4 Results 
2.4.1  Pharmacological inhibition of caspases in vivo during APAP toxicity.   
Treatment of fasted C57Bl/6 mice with 300 mg/kg APAP resulted in substantial liver 
injury as indicated by the increase in plasma ALT activities at 6 h (2.4.1.1A). During the 
following 18 h, the injury was further increased (2.4.1.1A). Liver injury was also 
confirmed by histology (2.4.1.1B,C), which showed extensive centrilobular necrosis 
(2.4.1.1C). Quantitatively, about 55% of hepatocytes were necrotic at 24 h (2.4.1.1B). 
APAP-induced liver injury caused a significant accumulation of neutrophils in the liver, 
which was only moderate at 6 h but dramatically increased by 24 h (2.4.1.1C,D). In 
order to inhibit IL-1β processing, animals were treated with the potent pan-caspase 
inhibitor Z-VD-fmk (Jaeschke et al., 2000) 2 h after APAP. Z-VD-fmk had no significant 
effect on plasma ALT activities or the area of necrosis (2.4.1.1A-C). In addition, Z-VD-
fmk had no significant effect on hepatic neutrophil accumulation at 6 or 24 h 
(2.4.1.1C,D). To evaluate the efficacy of the pan-caspase inhibitor, plasma IL-1β protein 
levels were measured at 6 h and 24 h after APAP. Six hours after APAP the circulating 
levels of IL-1β were increased three-fold over baseline (2.4.1.2A). This increase in IL-1β 
protein levels was completely prevented with the pan-caspase inhibitor demonstrating 
the efficacy of Z-VD-fmk to block caspase-1 activity (2.4.1.2A). Consistent with the 
function of caspase-1 to process pro-IL-1β, the caspase inhibitor did not affect the 
increase in IL-1β mRNA (2.4.1.2B). Furthermore, the pan-caspase inhibitor did neither 
modulate the mRNA or plasma protein levels of several other cytokines and 
chemokines including TNF-α, IL-18, IL-10, IL-6, KC and MIP-2 (data not shown).   
 
41 
 
2.4.1.1 
 
Acetaminophen-induced liver injury in C57Bl/6 mice with or without caspase inhibitor. 
Animals were first treated with 300 mg/kg APAP and then two hours later with 10 mg/kg 
Z-VD-fmk or vehicle control. (A) Plasma ALT at 6 h and 24 h; (B) area of necrosis at 24 
h. (C) Representative H&E-stained liver sections (x50 magnification) and 
immunohistochemistry for hepatic neutrophil accumulation (x200 magnification) are 
shown for controls and animals treated with APAP for 24 h. (D) Neutrophil numbers 
were quantified in 15 randomly selected high power fields (HPF; x400). Data represent 
means ± SE of n = 5 animals per group. *P<0.05 (compared to untreated controls). 
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2.4.1.2 
 
Interleukin-1β (IL-1β) protein levels in plasma (A) and hepatic IL-1β mRNA levels (B) 
were measured 6 and 24 h after administration of 300 mg/kg acetaminophen (APAP) in 
C57Bl/6 mice with or without the pan-caspase inhibitor (Z-VD-fmk). mRNA levels are 
expressed as IL-1β mRNA-to-β-actin mRNA ratio. The values of untreated controls were 
set as 1 and the fold change of the treated animals was calculated. Data represent 
means ± SE of n = 4-5 animals per group. *P<0.05 (compared to untreated control). 
#P<0.05 (compared to APAP-only equivalent time point) 
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2.4.2 Efficacy of Z-VD-fmk in the galactosamine/endotoxin liver injury model 
To further confirm the efficacy of the pan-caspase inhibitor, mice were treated with 
galactosamine/endotoxin (Gal/ET), which is a well established caspase-dependent 
model of hepatocellular apoptosis (Jaeschke et al., 1998). The 10 mg/kg dose and route 
of administration of Z-VD-fmk was effective in reducing 95% of the Gal/ET-induced 
increase in liver caspase-3 activity (2.4.2.1A). Blocking apoptosis also prevented 
secondary necrosis thereby reducing plasma ALT by nearly 90% (2.4.2.1B). To confirm 
the reduction in apoptotic cell death, liver sections were stained for DNA strand-breaks 
with the TUNEL assay. Gal/ET-induced caspase activation causes massive DNA 
fragmentation as indicated by the extensive staining of TUNEL-positive hepatocytes 
(2.4.2.1C). Again, the caspase-inhibitor almost completely prevented any TUNEL 
staining in these livers (2.4.2.1C). Together, these data confirm the high efficacy of this 
pan-caspase inhibitor against TNF-mediated apoptosis in the Gal/ET model of liver 
injury.  
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2.4.2.1 
 
Effects of 10 mg/kg Z-VD-fmk on galactosamine/endotoxin (GalN/ET)-induced liver 
injury. Animals were treated with saline or 700 mg/kg GalN and 100 μg/kg ET and then 
three hours later with 10 mg/kg Z-VD-fmk or vehicle control. (A) Caspase-3 activity at 6 
h; (B) Plasma ALT at 6 h. (C) Representative TUNEL staining of animals from each 
group. Data represent means ± SE of n = 3 animals per group.  *P<0.05 (compared to 
saline-treated controls) 
 
 
 
 
 
 
 
 
45 
 
2.4.3 APAP toxicity in IL-1 receptor-1 knockout mice 
The caspase inhibitor data indicate that IL-1β maturation does not appear to be a critical 
factor in APAP-induced toxicity in contrast to previous reports. To confirm these findings 
and to exclude a potential role of IL-1α, which is formed independent of the 
inflammasome, IL-1R1-/- mice were treated with APAP. Similar to the caspase inhibitor 
data, there was no significant effect of APAP on plasma ALT activities, area of necrosis 
and hepatic neutrophil accumulation in IL-1R1-/- mice compared to wild type animals at 
6 or 24 h after APAP (2.4.3.1A-C). Despite similar neutrophil recruitment, both hepatic 
cytokine/chemokines mRNA production and plasma cytokine/chemokine levels were 
quantified to determine if the inflammatory response is altered or delayed in mice 
lacking IL-1 signaling. Transcription of inflammatory genes in the liver is unchanged 
between wild-type and knockout mice at 6 and 24 h (2.4.3.2), however at the six hour 
time-point IL-6 and KC plasma protein levels are reduced relative to the treated wild-
type group (2.4.3.2), however these differences are not seen at 24 h.  Despite this 
apparent delay in formation of some of the cytokine/chemokine, liver injury as well as 
the quantity and distribution of neutrophils were unchanged (2.4.3.1C,D). 
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2.4.3.1 
 
Acetaminophen-induced liver injury in C57Bl/6 wild-type mice or IL-1R1-deficient mice. 
Animals were treated with 300 mg/kg APAP. (A) Plasma ALT at 6 h and 24 h; (B) area 
of necrosis at 24 h. (C) Representative H&E-stained liver sections (x50 magnification) 
and immunohistochemistry for hepatic neutrophil accumulation (x200 magnification) are 
shown for control and APAP-treated mice at 24 h; (D) Neutrophil numbers were 
quantified in 15 randomly selected high power fields (HPF; x400). Data represent 
means ± SE of n = 6 animals per group. *P<0.05 (compared to untreated controls).   
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2.4.3.2 
 
 
Hepatic mRNA levels and peripheral blood cytokine/chemokine concentrations were 
measured 6 h and 24 h after administration of 300 mg/kg APAP in C57Bl/6 wild type 
animals or IL-1R1-deficient mice. mRNA levels are calculated as the cytokine mRNA-to-
β-actin mRNA ratio. For mRNA calculations the values of untreated controls were set as 
1 and the fold change of the APAP-treated animals is shown. Data represent means ± 
SE of n = 5-6 animals per group. *P<0.05 (compared to control). #P<0.05 (compared to 
wild type equivalent time point) 
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2.4.4 Effects of supra-physiological levels of IL-1β during APAP toxicity 
Although our experiments so far were unable to support a role of IL-1β in the 
pathophysiology of APAP hepatotoxicity, we cannot rule out that the endogenous levels 
of IL-1β produced under our experimental conditions may have been too low to have a 
relevant impact on the injury mechanism. Therefore, we hypothesized that if IL-1β is 
critical for the injury via the recruitment of hepatic neutrophils or other leukocytes then 
an exacerbation of the injury should be observed when IL-1β is administered 
concurrently with APAP. Mice were injected i.p. with APAP and then given IL-1β or 
saline vehicle three hours later to mimic IL-1β, which would be produced during APAP-
induced sterile inflammation. Administration of IL-1β alone caused recruitment of 
neutrophils into the liver within 90 minutes (2.4.4.1D) without causing injury 
(2.4.4.1A,B). When IL-1β was administered after APAP, the additional inflammatory 
mediators enhanced APAP-induced hepatic neutrophil accumulation by 35% (2.4.4.1D) 
but had no effect on plasma ALT values or the area of necrosis induced by APAP alone 
(2.4.4.1A-C). These data further support our findings that even excess IL-1β did not 
further increase APAP-induced liver injury.  
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2.4.4.1 
 
Acetaminophen-induced liver injury in C57Bl/6 mice with or without IL-1β treatment. 
Mice were treated with 300 mg/kg APAP and/or 20 μg/kg IL-1β or vehicle. (A) Plasma 
ALT levels at 24 h; (B) area of necrosis at 24 h; (C) Representative H&E-stained liver 
sections (x50 magnification) and immunohistochemistry for hepatic neutrophil 
accumulation (x200 magnification) are shown for control and treated mice. (D) 
Neutrophil numbers were quantified in 15 randomly selected high power fields (HPF; 
x400). Data represent means ± SE of n = 6 animals per group. *P<0.05 (compared to 
untreated controls). #P<0.05 (compared to APAP only). 
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2.4.5 Neutrophil activation during IL-1β treatment 
In order to verify that the dose of IL-1β was able to activate neutrophils, the enhanced 
expression of CD11b on neutrophils and priming for NADPH oxidase-derived reactive 
oxygen formation was evaluated on peripheral neutrophils. Previous data showed a 
close correlation between the activation status of peripheral and hepatic neutrophils 
(see Chapater 4). C57Bl/6 mice were treated in vivo with saline (6 h), 300 mg/kg APAP 
(6 h), or 20 μg/kg IL-1β (1.5 h). Neutrophils were gated as Gr-1bright cells because 
previous literature demonstrated that Gr-1bright cells being the same population as Ly6G+ 
cells, which are neutrophils (Daley et al., 2008). APAP treatment caused no increase in 
CD11b expression versus control, and the very high dose of IL-1β caused only a partial 
activation of peripheral neutrophils resulting in two distinct cell populations expressing 
CD11b (2.4.5.1A,B).  Similarly, APAP did not cause increased ROS priming in 
peripheral neutrophils versus controls while supra-physiologic levels of IL-1β caused 
only a modest increase in ROS priming (2.4.5.1C,D).  
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2.4.5.1 
 
Neutrophil priming in peripheral blood. C57Bl/6 mice (n=4 per group) were treated with 
20 mL/kg saline (6 h), 300 mg/kg APAP (6 h), or 20 µg/kg IL-1β (1.5 h). Immediately 
after in vivo stimulation whole blood was stained for CD11b and Gr-1 surface 
expression and neutrophils (Gr-1bright cells) were analyzed by flow cytometry. (A) The 
mean CD11b fluorescent intensities of each treatment group are shown and (B) 
representative CD11b surface-expression dot plots and histograms for saline, APAP 
and IL-1β. To determine reactive oxygen species (ROS) priming after in vivo treatment, 
whole blood was stimulated ex vivo with PMA or saline. Upon PMA-induced ROS 
production DHR-123 is converted to R-123 and quantified in neutrophils by flow 
cytometry. (C) The mean ROS fluorescent intensities of each treatment group are 
shown and (D) representative ROS dot plots and histograms for saline, APAP and IL-
1β. Data represent means ± SE of n = 4 animals per group. *P<0.05 (compared to 
saline-treated controls). 
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2.5 Discussion 
The primary objective of this study was to evaluate the formation and pathophysiological 
significance of IL-1β during APAP-induced hepatotoxicity. Although there were recent 
reports implicating the inflammasome (caspase-1) and IL-1β signaling in APAP 
overdose (Chen et al., 2007; Imaeda et al., 2009), there were some concerns whether a 
single pro-inflammatory mediator like IL-1β could be such a dominant factor in the 
mechanism of injury as suggested by these authors.  
2.5.1 Caspase-1 and IL-1β formation during APAP hepatotoxicity 
The induction of IL-1 and IL-1β mRNA is well described after APAP overdose 
(Gardner et al., 2003; Cover et al., 2006; Ishibe et al., 2009; Imaeda et al., 2009; Martin-
Murphy et al., 2010). Our data are in agreement with the generally moderate 
transcriptional activation of IL-1β in response to APAP reported by these studies. In 
addition, we could demonstrate that there are significant but modest increases in 
mature IL-1β protein levels. Most importantly, this increase in IL-1β protein could be 
eliminated by inhibition of caspase-1 without affecting the mRNA levels. These data 
support the hypothesis that the increased formation of the mature IL-1β protein during 
APAP hepatotoxicity is dependent on caspases, most likely on caspase-1. These 
findings indicate that there is activation of the inflammasome, which contributes to the 
formation of pro-inflammatory mediators after APAP. Previous studies indicated that the 
release of DAMPs from necrotic hepatocytes may contribute to the formation of 
cytokines by macrophages through activation of toll-like receptors (Imaeda et al., 2009; 
Martin-Murphy et al., 2010).    
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2.5.2 Effect of IL-1β on the inflammatory response during APAP hepatotoxicity. 
In contrast to TNF receptor 1 or the Fas receptor, the IL-1 receptor does not have a 
death domain and therefore cannot directly trigger cell death. Thus, the only way IL-1β 
and the IL-1 receptor can be involved in cell injury is through the activation of cytotoxic 
leukocytes (Sims and Smith, 2010). During APAP-induced injury, the first leukocytes 
observed in the liver are neutrophils (Lawson et al., 2000), which have the capacity to 
severely enhance liver injury (Jaeschke, 2006). IL-1 is a potent activator of neutrophils 
that can trigger substantial hepatic neutrophil recruitment (Bajt et al., 2001). Our data 
with IL-1β confirm these findings and additionally show that adding high doses of 
endogenous IL-1β during APAP toxicity has an additive effect on hepatic neutrophil 
accumulation. However, eliminating the increase in IL-1β formation had no effect on the 
number of liver neutrophils. Thus, together these data suggest that the endogenous IL-
1β formation during APAP hepatotoxicity is insufficient to have a relevant impact on 
hepatic neutrophil recruitment. Because IL-1R-deficient mice did not have less 
neutrophils in the liver compared to wildtype animals, it indicates that neither 
endogenous IL-1β nor IL-1 affects hepatic neutrophil accumulation. In addition, 
treatment with high doses of IL-1β activated and primed circulating neutrophils, which 
closely reflect the activation status of liver neutrophils (see Chapter 4). APAP alone did 
not activate circulating or liver neutrophils as indicated by absence of enhanced CD11b 
expression and no priming for ROS formation (2.4.5.1 and Chapter 4). This supports the 
conclusion that endogenously formed IL-1β is also insufficient to activate neutrophils. 
These findings, although opposite to what has been postulated (Chen et al., 2007; 
Imaeda et al., 2009), are not surprising given the substantial number of cytokines, 
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chemokines and other mediators formed during the extensive cell damage caused by 
APAP (Lawson et al., 2000; Gardner et al., 2003; Cover et al., 2006; Ishibe et al., 2009; 
Imaeda et al., 2009; Martin-Murphy et al., 2010).  
Additional inflammatory cells activated during APAP hepatotoxicity include the resident 
macrophages of the liver (Kupffer cells) and newly recruited tissue macrophages 
derived from blood monocytes (Laskin, 2009). Emerging evidence indicates that Kupffer 
cells are mainly involved in the formation of pro- and anti-inflammatory cytokines but 
less in direct cytotoxicity (Ju et al., 2002; Martin-Murphy et al., 2010). The newly 
recruited tissue macrophages arrive mainly after the injury already peaked and appear 
to be involved in the resolution of inflammation and removal of necrotic cell debris 
(Dambach et al., 2002; Holt et al., 2008). Monocyte chemoattractant protein (MCP-1) 
rather than IL-1β is involved in the late monocyte recruitment (Dambach et al., 2002; 
Holt et al., 2008).  
2.5.3 IL-1β and APAP-induced liver injury 
The most critical question is whether IL-1β is involved in the injury process. In a 
previous paper it was reported that IL-1R-deficient mice are more than 90% protected 
against APAP hepatotoxicity based on plasma ALT activities (Chen et al., 2007). Using 
the same gene knockout mice, we did not find any evidence of protection at early or late 
time points after APAP overdose. When the authors used a combination of neutralizing 
antibodies against IL-1β, IL-1, and IL-1R1, the protective effect was only 30% (Chen et 
al., 2007). Thus, even this study shows highly variable results on the role of IL-1. In 
addition, a second report claimed a critical role specifically for IL-1β due to the fact that 
gene knock-out mice of caspase-1 and different components of the inflammasome were 
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partially protected (Imaeda et al., 2009). In this study, neutralizing IL-1β or deficiency of 
IL-18, Nalp3, caspase-1, and ASC showed reduced mortality and lower plasma ALT 
levels by 50-60% after APAP overdose (Imaeda et al., 2009). The authors concluded 
that the transcriptional activation of IL-1β and IL-18 together with the processing to the 
mature cytokine through caspase-1 is critical for APAP hepatotoxicity (Imaeda et al., 
2009). In sharp contrast, our data are consistently showing no relevant effect of IL-1β 
(or IL-1) in the pathophysiology. The amount of IL-1β generated was minor and 
insufficient to trigger activation and recruitment of neutrophils into the liver. In addition, 
we did not find significant upregulation of IL-18 mRNA after APAP treatment. A caspase 
inhibitor, which completely prevented the APAP-induced mature IL-1β formation, did 
neither affect hepatic neutrophil recruitment nor liver injury. Furthermore, the IL-1R1-
deficient mouse was not protected or showed reduced inflammation. Finally, even 
treating the animals with an extremely high dose of IL-1β, which by itself can activate 
neutrophils and cause their accumulation in the liver, did enhance the overall neutrophil 
count in the liver but had no effect on the injury. These findings are consistent with a 
large number of different experiments that all demonstrated that the inflammatory 
response with hepatic neutrophil infiltration does not increase APAP-induced liver injury 
(Lawson et al., 2000; James et al., 2003; Cover et al., 2006). In these experiments, 
blocking or eliminating adhesion molecules which have been shown to be required for 
neutrophil cytotoxicity in the liver, i.e. CD18 and intercellular adhesion molecule-1 
(ICAM-1) (Jaeschke and Smith, 1997), had no effect against APAP hepatotoxicity 
(Lawson et al., 2000; Chapter 4). Furthermore, inhibiting or eliminating the capacity of 
neutrophils to generate reactive oxygen species, which is critical for neutrophil 
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cytotoxicity in vivo (Jaeschke et al., 1999; Gujral et al., 2004; Hasegawa et al., 2005), 
had no effect on acetaminophen toxicity (James, et al., 2003; Cover et al., 2006). Most 
importantly, even when large amounts of pro-inflammatory mediators are either injected 
or generated through endotoxin during APAP-induced liver injury, the additional 
activated neutrophils do not affect the overall injury. Thus, even if sufficient IL-1 or IL-18 
would have been generated during APAP overdose, there is no evidence that these 
phagocytes contribute to the injury.  
Why is there such a difference in the results and conclusions between studies despite 
the use of the same mouse strain and similar doses of APAP? There is no easy answer. 
However, in the previous studies where extensive protection was shown in a large 
number of different gene knock-out mice, it was never tested if there are differences in 
metabolic activation or other changes in the intracellular signal transduction pathways 
(Chen et al., 2007; Imaeda et al., 2009). Furthermore, the cells that actually cause the 
toxicity were never identified. Thus, the mechanisms of APAP toxicity in these knock-out 
mice remained unclear and it was not excluded that off-target effects could have been 
responsible for the protection. In support of this hypothesis, it was recently shown that 
IL-1 receptor antagonist-deficient (IL-1ra-/-) mice showed reduced liver injury to APAP 
(Ishibe et al., 2009). Since IL-1ra blocks the signaling of IL-1α and IL-1β through IL-1R1 
and prevents the intracellular recruitment of IL-1RAP (Sims and Smith, 2010), this 
finding is in direct contrast to the hypothesis that the IL-1 axis increases injury. Most 
importantly, this study demonstrated that IL-1ra-/- mice have decreased metabolic 
activity and therefore generate less reactive metabolite, i.e. the protection was caused 
by modulation of intracellular events rather than inflammation (Ishibe et al., 2010). 
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However, consistent with our data, Imaeda et al. (2009) showed only a 6% increase of 
mature IL-1β in plasma after APAP. As we demonstrated, such a minute change in 
circulating IL-1β has no chance to cause neutrophil activation and recruitment into the 
liver and, therefore, it remained unclear how the activity of the inflammasome could 
have had any impact on APAP-induced liver injury.  
2.5.4 Summary 
Comprehensive analysis of the formation and potential role of IL-1β in the 
pathophysiology of APAP hepatotoxicity revealed no support that this cytokine is 
generated in sufficient quantities to activate neutrophils and neither inhibition of 
caspases and the inflammasome nor deficiency of the IL-1R had any impact on APAP-
induced inflammation and liver injury. Although these data are opposite to several 
recent papers (Chen et al., 2007; Imaeda et al., 2009), they are fully consistent with our 
previous findings that neutrophils do not increase liver injury after APAP overdose. 
Thus, the inflammatory cascade is a less relevant therapeutic target than the 
intracellular signaling pathways to attenuate APAP-induced liver injury. 
 
 
 
 
 
 
 
58 
 
 
 
 
 
 
 
 
 
 
Chapter 3 
Role of the Nalp3 inflammasome and sterile inflammation during APAP overdose 
 
 
 
 
 
 
 
Reproduced from: 
Toxicology and Applied Pharmacology, 252(3):289-297, Role of the Nalp3 
inflammasome in acetaminophen-induced sterile inflammation and liver injury, 2011, 
with permission from Elsevier. 
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3.1 Abstract 
Acetaminophen (APAP) overdose is the leading cause of acute liver failure in the US 
and UK. Recent studies implied that APAP-induced injury is partially mediated by 
interleukin-1β (IL-1β), which can activate and recruit neutrophils, exacerbating injury. 
Mature IL-1β is formed by caspase-1, dependent on inflammasome activation. The 
objective of this investigation was to evaluate the role of the Nalp3 inflammasome on 
release of damage associated molecular patterns (DAMPs), hepatic neutrophil 
accumulation and liver injury (ALT, necrosis) after APAP overdose. Mice deficient for 
each component of the Nalp3 inflammasome (Caspase-1, ASC and NALP3) were 
treated with 300 mg/kg APAP for 24 h; these mice had similar neutrophil recruitment 
and liver injury as APAP-treated C57Bl/6 wildtype animals. In addition, plasma levels of 
DAMPs (DNA fragments, keratin-18, hypo- and hyper-acetylated forms of high mobility 
group box-1 protein) were similarly elevated with no significant difference between 
wildtype and gene knockout mice. In addition, aspirin treatment, which has been 
postulated to attenuate cytokine formation and the activation of the Nalp3 
inflammasome after APAP, had no effect on release of DAMPs, hepatic neutrophil 
accumulation or liver injury. Together these data confirm the release of DAMPs and a 
sterile inflammatory response after APAP overdose. However, as previously reported 
minor endogenous formation of IL-1β and the activation of the Nalp3 inflammasome 
have little impact on APAP hepatotoxicity. It appears that the Nalp3 inflammasome is 
not a promising therapeutic target to treat APAP overdose.   
60 
 
3.2 Introduction 
Acetaminophen (APAP) is a widely used safe analgesic and antipyretic drug. However, 
an overdose can cause hepatotoxicity and even liver failure in animals and humans 
(Larson et al., 2005). Early mechanistic studies identified formation of a reactive 
metabolite, glutathione depletion and covalent binding to cellular proteins as critical 
initiating events in the toxicity (Cohen et al., 1997; Nelson, 1990). More recent studies 
showed the central role of mitochondrial dysfunction, including oxidant stress and 
peroxynitrite formation, the mitochondrial membrane permeability transition pore 
opening (MPT) and nuclear DNA fragmentation as propagation events in APAP-induced 
cell death in the liver (Jaeschke et al., 2003; Jaeschke and Bajt, 2006).  
In recent years the new concept emerged that APAP-induced cell death triggers a 
neutrophilic inflammatory response, which has the potential to further exacerbate the 
existing injury (Jaeschke, 2005; Liu and Kaplowitz, 2006). A neutrophil-mediated injury 
component has been identified in a variety of experimental conditions including hepatic 
ischemia-reperfusion injury, endotoxemia, alcoholic hepatitis, obstructive cholestasis 
and in several drug-induced liver injury models (Jaeschke, 2006; Jaeschke and 
Hasegawa, 2006). It has been recognized that the initial cell death triggers formation of 
inflammatory mediators including activated complement factors (Jaeschke et al., 1993), 
cytokines and chemokines (Okaya and Lentsch, 2003). A variety of molecules released 
from necrotic cells were identified that could induce cytokine formation through 
stimulating toll-like receptors (TLRs) (Schwabe et al., 2006). These molecules 
collectively termed damage-associated molecular patterns (DAMPs) include high 
mobility group box-1 (HMGB1) protein, heat shock proteins (HSPs), and DNA fragments 
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(Bianchi, 2007). Similar DAMPs are also released and correlate with the degree of 
hepatic damage observed during APAP-induced liver injury (Antoine et al., 2009, 2010; 
Jahr et al., 2001; Martin-Murphy et al., 2010; Scaffidi et al., 2002) and are responsible 
for hepatic neutrophil accumulation (Scaffidi et al., 2002).  
Despite extensive evidence against a direct involvement of neutrophils in APAP 
hepatotoxicity (Bauer et al., 2000; Cover et al., 2006; James et al., 2003; Lawson et al., 
2000; Welty et al., 1993), several recent reports suggested a critical role of interleukin-
1α (IL-1α) (Chen et al., 2007) and in particular IL-1β, in the pathophysiology (Imaeda et 
al., 2009). It was shown that stimulation of TLR9 by DNA fragments during early APAP-
induced cell death can lead to the transcriptional activation of the IL-1β gene resulting in 
the formation of pro-IL-1β (Imaeda et al., 2009). The pro-form of IL-1β has to be 
proteolytically cleaved by activated caspase-1 (interleukin-1 converting enzyme) to yield 
the active cytokine (Sims and Smith, 2010). Caspase-1 activation is regulated by the 
assembly of the inflammasome, which consists of Nalp3 (NACHT, LRR, and pyrin 
domain-containing protein 3), ASC (apoptosis-associated speck-like protein containing 
a CARD), and caspase-1 (Kanneganti et al., 2007; Lamkanfi and Dixit, 2009). Imaeda et 
al. (2009) showed reduced APAP-mediated injury in gene knockout mice of each 
individual component of the inflammasome, suggesting an important role of 
inflammasome activation and IL-1β formation in the pathophysiology of experimental 
APAP hepatotoxicity. Moreover, inhibition of inflammasome activation by aspirin 
resulted in protection from APAP hepatotoxicity (Imaeda et al., 2009). These intriguing 
results open up new avenues of research, provide further opportunities for therapeutic 
strategies to treat APAP hepatotoxicity and can potentially lead to the identification of 
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human susceptibility factors for drug-induced liver injury. However, there are conflicting 
data associated with this concept that require reconciliation. One of the most critical 
observations arguing against a significant role played by the inflammasome is the fact 
that IL-1 signaling cannot directly induce cell death in vivo (Sims and Smith, 2010). The 
only way IL-1α or -1β can cause relevant liver injury is through activation of 
inflammatory cells, i.e. neutrophils (Bajt et al., 2001), and exacerbation of 
acetaminophen-induced hepatocyte damage. However, neutrophils are unlikely to 
cause liver injury after APAP overdose (Bauer et al., 2000; Cover et al., 2006; James et 
al., 2003; Lawson et al., 2000; Welty et al., 1993). In addition, we have shown that a 
potent pan-caspase inhibitor prevented mature IL-1β formation during APAP-induced 
liver injury (Williams et al., 2010b). However, various pan-caspase inhibitors, despite 
their high efficacy to inhibit caspases in vivo, had consistently no effect on APAP-
mediated neutrophil accumulation or liver injury (Antoine et al., 2009; Lawson et al., 
1999). Thus, evaluation of the role of the Nalp3 inflammasome and caspase-1 in APAP 
toxicity in vivo resulted in opposing findings when investigated through pharmacological 
interventions to inhibit caspase-1 activity compared to a genetic approach to eliminate 
this enzyme (Imaeda et al., 2009, Chapter 2). In order to reconcile these contradicting 
results, the objective of this investigation was to further re-evaluate the contribution of 
activation of the Nalp3 inflammasome in the pathogenesis of APAP hepatotoxicity by 
using gene knockout mice of all components and by using aspirin treatment.  
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3.3 Materials and Methods 
3.3.1 
Animals. Eight to twelve week old male ASC-/-, Caspase-1-/-, Nalp3-/- and C57BL/6 
control mice with an average weight of 18 to 24 g were bred and maintained at St. Jude 
Children's Research Hospital (Memphis, TN). Nalp3-/-, ASC-/- and Caspase-1-/- mice 
backcrossed to C57Bl/6 background for at least 10 generations have been described 
previously (Shaw et al., 2010). Additionally, C57BL/6 mice were bred and housed at the 
University of Liverpool (Liverpool, UK). All animals were housed in environmentally 
controlled rooms with 12 h light/dark cycle and allowed free access to food and water. 
Experiments followed the criteria of the National Research Council for the care and use 
of laboratory animals in research and guidelines set forth by the University of Liverpool 
Animal Ethics Committee, respectively.  
3.3.2 
Experimental design. All chemicals were purchased from Sigma Chemical Co. (St. 
Louis, MO) unless otherwise stated.Mice were intraperitoneally (i.p.) injected with 300 
mg/kg APAP (dissolved in warm saline) after overnight fasting or with an equivalent 
volume of saline.  Additionally, some mice were given aspirin via drinking water (0.06 
mg/mL or 1.0 mg/mL) for three days and fasted overnight prior to 530 mg/kg APAP 
(i.p.). All animals were sacrificed 24 h after APAP. Blood was drawn into heparinized 
syringes for measurement of alanine aminotransferase (ALT) activity (Pointe Scientific, 
Canton, MI) and then stored at -80C. The liver was removed and was rinsed in cold 
saline; liver sections were fixed in 10% phosphate buffered formalin for histological 
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analyses. The remaining liver lobes were snap-frozen in liquid nitrogen and stored at -
80C.   
 3.3.3 
Histology.  Formalin-fixed tissue samples were embedded in paraffin and 5 m sections 
were cut. Sections were stained with hematoxylin and eosin (H&E) for blinded 
evaluation of the areas of necrosis by the pathologist. The percent of necrosis was 
estimated by evaluating the number of microscopic fields with necrosis compared to the 
cross sectional area. Additional sections were stained for neutrophils using the anti-
mouse neutrophil allotypic marker antibody (AbD Serotec, Raleigh, NC) as previously 
described (Williams et al., 2010a). Positively stained neutrophils consistent with cellular 
morphology were quantified in 15 high power fields (HPF).  Some sections were also 
stained for terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) in 
situ cell death assay (Roche, Indianapolis, IN) as previously described (Lawson et al., 
1999). 
3.3.4 
mRNA expression. Quantification of mRNA expression was performed by real-time PCR 
(RT-PCR) analysis as described previously (Bajt et al., 2008). cDNA was made by 
reverse transcription of total tissue RNA by M-MLV reverse transcriptase in the 
presence of random primers (Invitrogen, Carlsbad, CA).  Forward and reverse primers 
for the genes were designed using Primer Express software (Applied Biosystems, 
Foster City, CA). After cDNA concentration normalization, SYBR green PCR Master Mix 
(Applied Biosystems) was used for real-time PCR analysis. The relative differences in 
expression between groups were expressed using cycle time (Ct) values generated by 
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the ABI 7900 instrument (Applied Biosystems).  All genes evaluated were first 
normalized to the β-actin gene and then expressed as a fold increase relative to control 
arbitrarily set as 1.0. Calculations are made by the 2^(-ddCt) formula. 
3.3.5 
Glutathione quantification. Glutathione (GSH) and glutathione disulfide (GSSG) were 
measured from liver homogenate using the Tietze method as previously described in 
detail (Jaeschke and Mitchell, 1990). Briefly, frozen tissue was homogenized in 
sulfosalicylic acid/EDTA. For total GSH determination samples were assayed using 
dithionitrobenzoic acid. Similarly, measurement of GSSG was performed using the 
same method after trapping and removal of GSH with N-ethylmaleimide.  
3.3.6 
Plasma DNA fragments. To quantify the release of nuclear DNA fragments into plasma 
the cell death detection ELISA (Roche, Indianapolis, IN) was used according to the 
manufacturer’s instructions.   
3.3.7 
Plasma HMGB1 and Keratin-18. Quantification of plasma HMGB1 and Keratin-18 were 
previously described in detail (Antoine et al. 2009, 2010).  Briefly, serum proteins were 
immunoprecipitated and subsequently analyzed by LC-MS/MS. 
3.3.8 
Statistics.  All results were expressed as mean  SE. Comparisons between 
multiple groups were performed with one-way ANOVA or, where appropriate, by 
two-way ANOVA, followed by a post hoc Bonferroni test. If the data were not 
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normally distributed, the Kruskal-Wallis Test (nonparametric ANOVA) followed by 
Dunn’s Multiple Comparisons Test was used. P < 0.05 was considered significant. 
67 
 
3.4 Results 
3.4.1 Liver injury and inflammation in Nalp3 inflammasome-deficient mice 
To determine if the Nalp3 inflammasome is critical for APAP-induced toxicity, 
inflammasome-deficient mice (ASC-/-, Caspase-1-/- and Nalp3-/-) and C57BL/6 wild-
type mice were given APAP and sacrificed 24 h later. Liver injury was determined by 
plasma ALT (3.4.1.1A) and histological quantification of liver necrosis (3.4.1.1B and 
3.4.1.2). In contrast to previously published results (Imaeda et al., 2009), the injury in all 
genotypes was similar demonstrating the Nalp3 inflammasome does not appear to be a 
critical factor in murine APAP-induced liver injury. Additionally, it was hypothesized that 
APAP-induced sterile inflammation and IL-1β production mediates immune cell 
infiltration, potentiating injury. To evaluate if Nalp3 inflammasome activation is important 
for neutrophil recruitment during APAP overdose, hepatic neutrophils were quantified.  
Consistent with the injury, total hepatic neutrophil counts were not different between 
genotypes (3.4.1.1C and 3.4.1.2), which agrees with previously published results 
demonstrating IL-1β does not participate in neutrophil recruitment during APAP-
overdose (Chapter 2). To further evaluate inflammation, hepatic mRNA levels for 
various cytokines, chemokines and adhesion molecules were compared (3.4.1.3).  
Interestingly, IL-18, a cytokine which also requires caspase-1 processing, was down-
regulated after APAP overdose and IL-1β was only slightly increased similar to 
previously published results (Chapter 2). Despite the absence of each Nalp3 
inflammasome component, there was no alteration in gene expression between 
genotypes of any cytokine (IL-1β, IL-18, IL-10, IL-6, TNF-α), chemokines (MIP-1α, MIP-
1β, MIP-2α, MCP-1), or adhesion molecule (ICAM-1) measured (3.4.1.3). This 
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demonstrates a nearly identical inflammatory response, which appears to be 
independent of the Nalp3 inflammasome, during APAP overdose. 
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3.4.1.1 
 
Liver injury and hepatic neutrophil recruitment after APAP-overdose in Nalp3 
inflammasome-deficient mice. Liver injury in C57BL/6 (WT), ASC-/-, Caspase-1-/- and 
Nalp3-/- mice was measured by plasma ALT (A) and by histological scoring of liver 
necrosis (B) 24 hours after APAP overdose. Hepatic neutrophil recruitment was also 
quantified at 24 h by immunohistochemistry and expressed as total liver neutrophils 
counted in 15 high power fields (x400 magnification) (C). *P < 0.05 compared to 
untreated control. 
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3.4.1.2 
 
TUNEL, H&E and neutrophil staining in Nalp3-inflammasome deficient mice. Liver 
tissue sections were stained with the TUNEL assay (x50 magnification) to demonstrate 
equivalent DNA damage in all genotypes [C57BL/6 (WT), ASC-/-, Caspase-1-/- and 
Nalp3-/- mice]. Area of necrosis was determined by H&E staining (x50 magnification). 
Neutrophil recruitment was identified by immunohistochemistry (x200 magnification). 
Control panels shown are C57BL/6 saline treated mice; knockout saline-treated mice 
look morphologically identical (not shown).  
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3.4.1.3
 
Hepatic mRNA levels 24 h after administration of 300 mg/kg APAP in C57BL/6 wild type 
animals or knockout mice. mRNA levels are calculated as the cytokine mRNA-to-β-actin 
mRNA ratio. For mRNA calculations the values of untreated controls were set as 1 and 
the fold change of the APAP-treated animals is shown. Data represent means ± SE of n 
= 5 animals per group. All data shown are significant as compared to untreated 
genotype-matched controls (P<0.05). No gene from APAP-treated knockout animals 
was significantly different as compared to APAP-treated C57BL/6 controls. 
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3.4.2 APAP-induced oxidant stress in Nalp3 inflammasome-deficient mice 
To evaluate liver glutathione recovery and oxidant stress, hepatic GSH and GSSG 
levels were measured. All genotypes had equivalent GSH recovery at 24 h after APAP 
(3.4.2.1A) and untreated control mice had equivalent hepatic GSH levels between 
genotypes (data not shown). In addition, all genotypes had increased GSSG levels over 
controls with ASC-/- and Nalp3-/- groups having further elevated GSSG levels versus 
wildtype APAP-treated animals (3.4.2.1B). Despite significantly increased GSSG to 
GSH ratios in all Nalp3 inflammasome-deficient mice compared to wildtype controls 
(3.4.2.1C) there was no alteration in injury (3.4.1.1A,B). These data show increased and 
somewhat variable levels of oxidative stress between genotypes but this variability did 
not impact liver injury. 
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3.4.2.1 
 
Liver glutathione and GSSG in Nalp3-inflammasome deficient mice. Total GSH was 
measured in liver tissue homogenate of saline treated C57BL/6 (control) and C57BL/6 
(WT), ASC-/-, Caspase-1-/- and Nalp3-/- at 24 h after APAP (A). GSSG was measured 
at 24 h after APAP (B) and the ratio of GSSG to total GSH is shown (C). Knockout 
saline-treated control mice are not different from C57BL/6 saline-treated controls (not 
shown). *P < 0.05 compared to saline control.  #P < 0.05 compared to APAP-treated 
C57BL/6 mice. 
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3.4.3 DAMP release is unaltered in Nalp3 inflammasome-deficient mice 
Necrotic cells release damage associated molecular patterns (DAMPs) which can 
initiate an inflammatory response that was implicated in promoting further injury. 
DAMPs include high mobility group box-1 (HMGB1) proteins and DNA fragments 
(Bianchi, 2007). To eliminate the possibility that inflammasome-deficient mice have 
altered DAMP release, nuclear DNA fragments, keratin-18 and HMGB1 proteins were 
measured in plasma (3.4.3.1A-C). Consistent with cellular injury, the increase in plasma 
DNA fragments was similar in all genotypes (3.4.3.1A). Total keratin-18 (K-18) is 
another useful biomarker to demonstrate cellular injury (Antoine et al., 2009). Indeed, 
there was a significant increase in plasma keratin-18 compared to controls but no 
differences in plasma concentrations between genotypes (3.4.3.1B). Another DAMP 
released after APAP overdose is HMGB1. In addition to total plasma HMGB1 
(3.4.3.1C), the hyper- and hypo-acetylated forms of the protein have been shown to 
originate from innate immune inflammation and necrotic tissue, respectively (Antoine et 
al., 2009). Correlating with equivalent inflammation and injury, there were no differences 
between genotypes of total, hyper- or hypo-acetylated HMGB1 (3.4.3.1C,D), and no 
differences in plasma DNA fragments, K-18 or HMBG1 were observed between 
genotypes of saline treated animals (data not shown). These data show equivalent 
DAMP release and a subsequent equivalent sterile inflammation with or without the 
presence of functional Nalp3 inflammasome. 
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3.4.3.1 
 
Quantification of plasma DAMPs in Nalp3-inflammasome deficient mice. DNA fragments 
were measured in plasma of saline treated C57BL/6 (control) and C57BL/6 (WT), ASC-
/-, Caspase-1-/- and Nalp3-/- at 24 h after APAP (A) and expressed as percent of 
control. Similarly, total plasma keratin-18 (B), total plasma HMGB1 (C), and hypo- and 
hyper-acetylated plasma HMGB1 (D) were measured. Knockout saline-treated mice are 
not different from C57BL/6 saline-treated controls (not shown). *P < 0.05 compared to 
saline control. 
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3.4.4 Aspirin does not alter APAP toxicity or DAMP release 
It was hypothesized that aspirin (acetylsalicylic acid, ASA) is capable of inhibiting the 
Nalp3 inflammasome and it was reported that pretreatment with ASA in drinking water 
reduced APAP-induced injury (Imaeda et al., 2009). This study was repeated with the 
ASA dose previously published (0.06 mg/mL in drinking water) as well as a higher dose 
(1.0 mg/mL in drinking water). Data presented are for only the high dose of ASA 
because no effect on injury was observed for either dose. ASA in the drinking water of 
mice caused no liver injury nor was it capable of reducing the APAP-induced liver injury 
as measured by plasma ALT activities (3.4.4.1A) or the area of necrosis (3.4.4.1B,D). 
ASA pretreatment did not alter hepatic GSH levels nor did it cause differences is GSH 
recovery after overdose indicating it did not affect APAP metabolism (data not shown). 
ASA pretreatment caused a trend in decreasing hepatic neutrophil recruitment after 
APAP overdose, but the reduction was not statistically significant (3.4.4.1C,D). In 
addition, ASA pretreatment caused no alterations in DAMP release which is consistent 
with the results observed in Nalp3 inflammasome knockout mice. The APAP-induced 
increase in plasma levels of keratin-18 (3.4.4.2A), total HMGB1 (3.4.4.2B) and hyper- 
and hypo-acetylated HMGB1 (3.4.4.2C) were not significantly affected by ASA 
treatment. As a whole the genetic elimination of the Nalp3 inflammasome and 
pharmacologic inhibition of the Nalp3 inflammasome with ASA did nothing to alter 
APAP-induced injury. 
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3.4.4.1 
 
Liver injury and hepatic neutrophil recruitment in aspirin-pretreated mice after APAP-
overdose. ALT (A) was measured in the plasma of C57BL/6 mice pretreated with or 
without aspirin (ASA) in the drinking water and then subjected to APAP-overdose or 
saline injection. Similarly, histological area of necrosis (B), and neutrophil accumulation 
were quantified (C) were measured as previously described. Representative sections 
with H&E and neutrophil staining are shown (D). *P < 0.05 compared to the respective 
control with or without ASA. 
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3.4.4.2 
 
Quantification of plasma DAMPs in aspirin-pretreated mice. Total keratin-18 (A) was 
measured in the plasma of C57BL/6 mice pretreated with or without aspirin (ASA) in the 
drinking water and then subjected to APAP-overdose or saline injection. Similarly, total 
plasma HMGB1 (B), and hypo- and hyper-acetylated HMGB1 (C) were measured. *P < 
0.05 compared to the respective control with or without ASA. 
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3.5 Discussion 
3.5.1 Role of the Nalp3 inflammasome in APAP-induced liver injury 
The main objective of this investigation was to reconcile apparently contradictory results 
regarding the importance of the Nalp3 inflammasome in APAP hepatotoxicity obtained 
by different groups using a genetic versus a pharmacological approach. Imaeda et al. 
(2009) reported significantly reduced liver injury and improved survival in ASC-/-, Nalp3-
/- and caspase1-/- mice. Although it was only shown for Nalp3-/- mice that the APAP-
induced increase in IL-1β protein formation was prevented, the assumption was that all 
knockout mice were partially protected because processing of pro-IL-1β to the active, 
pro-inflammatory cytokine IL-1β should have been prevented when caspase-1 as part of 
the Nalp3 inflammasome was nonfunctional (Imaeda et al., 2009). These conclusions 
are consistent with a previous report showing that IL-1 receptor-deficient mice were 
almost completely (95%) protected against APAP-induced liver injury (Chen et al., 
2007). It was assumed that inflammatory cells played a deleterious role in the 
pathogenesis (Imaeda et al., 2009; Chen et al., 2007). In contrast to these reports, our 
current findings indicate very clearly that ASC-/-, Nalp3-/- and caspase1-/- knock-out 
mice are neither protected (ALT, area of necrosis, oxidant stress, DNA damage) nor do 
these animals show any evidence of a reduced inflammatory response (cytokine and 
chemokine formation, hepatic neutrophil accumulation). These data are fully consistent 
with our previous report where we found not only increases of IL-1β mRNA after APAP 
overdose but also moderate increases in caspase-dependent mature IL-1β protein 
formation (Chapter 2). However, the caspase inhibitor had no protective effect on liver 
injury or hepatic neutrophil accumulation, a concept consistent with other published 
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findings (Antoine et al., 2009). It is notable that the 300% increase of IL-1β formation 
after APAP as reported in our study (Chapter 2) is actually higher than the 13% 
increase measured by Imaeda et al. (2009). The mechanistic basis of this still requires 
further investigation. Independent of these differences in pathological outcome, both 
studies clearly show that the absolute plasma levels of IL-1β protein are very low even 
after APAP overdose (Imaeda et al., 2009; Chapter 2). Thus, in order to assess if levels 
of IL-1β that have been shown to activate and recruit neutrophils into the liver (Bajt et 
al., 2001), can impact APAP toxicity, animals were treated with pharmacological levels 
of murine recombinant IL-1β (about 3-4 orders of magnitude above endogenous 
concentrations). Although this indeed caused more recruitment of activated neutrophils 
into the liver, it still had no effect on liver injury (Chapter 2). In agreement with these 
findings, IL-1R-/- mice were not protected against APAP hepatotoxicity (Chapter 2). 
These data together indicate that despite the fact that some IL-1β is generated in a 
caspase-dependent manner after APAP overdose, it is highly unlikely that this minor, 
endogenously formed cytokine has any major impact on the inflammatory response 
induced during APAP hepatotoxicity. In addition, neither our previous study (Chapter 2) 
nor our present experiments showed any evidence for increased formation of IL-18, 
another cytokine that is processed by caspase-1, after APAP overdose. Moreover, 
theoretically, any pathophysiological effect of both cytokines would have to involve 
cytotoxicity mediated by inflammatory cells. However, there is extensive experimental 
evidence to suggest that neutrophils are not involved in APAP-induced liver injury 
(Bauer et al., 2000; Cover et al., 2006; James et al., 2003; Lawson et al., 2000; Welty et 
al., 1993). Thus, based on the currently reported data from our study activation of the 
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Nalp3 inflammasome does not play a critical role in the exacerbation of APAP 
hepatotoxicity.  
In addition to playing a critical role in the formation of the Nalp3 inflammasome, recent 
reports have suggested that ASC is involved in inflammasome-independent cellular 
functions such as lymphocyte survival (Shaw et al., 2010), antigen-induced T cell 
activation by dendritic cells (Ippagunta et al., 2010) and antigen-specific humoral 
immunity (Ellebedy et al., 2011). The mechanism(s) underlying the critical role of ASC in 
these functions is still unknown, but it is possible ASC is involved in other 
inflammasome-independent functions in various cell types. However, ASC-/- mice 
developed APAP-induced liver injury to the same degree as wildtype animals 
suggesting that all inflammasome-dependent and inflammasome-independent functions 
of ASC do not play a relevant role in APAP hepatotoxicity.  
3.5.2 The role of aspirin in APAP hepatotoxicity  
Imaeda et al. (2009) also reported that a low dose of aspirin (N-acetylsalicylic acid) can 
reduce APAP hepatotoxicity independent of its effect on platelet aggregation or 
cyclooxygenase-1 or -2. It was concluded that aspirin protected due to inhibition of the 
transcriptional activation of cytokine formation (IL-1β, IL-18, TNF-α and interferon-γ) and 
also inhibition of the Nalp3 inflammasome pathway, which processes IL-1β and IL-18 
(Imaeda et al., 2009). Again, the assumption was that the reduced cytokine formation 
attenuates liver injury through reduced inflammatory cell activation and recruitment. 
However, using the same pretreatment regimen as described by Imaeda et al. (2009) 
with the same or higher doses of aspirin, no significant effect on APAP-induced liver 
injury was observed when compared to APAP-treated mice in our study. Aspirin 
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treatment showed a trend to attenuate the number of neutrophils in the liver but the 
overall effect was statistically not significant and indeed, the quantification of serum 
biomarkers of toxicity (ALT, HMGB1, K-18) was not different between groups. These 
data further support the concept that aspirin pretreatment has no significant effect on 
the overall extent of experimental APAP hepatotoxicity. APAP metabolism was shown 
to be unaffected by aspirin pretreatment in our investigation, but this was not assessed 
in the previous study (Imaeda et al., 2009). Thus, in our hands aspirin was not effective 
in preventing APAP hepatotoxicity. Even if aspirin would reduce hepatic neutrophil 
recruitment, the fact that many other interventions against neutrophils were ineffective in 
this model (Bauer et al., 2000; Cover et al., 2006; James et al., 2003; Lawson et al., 
2000; Welty et al., 1993), are consistent with the lack of protection by aspirin. 
3.5.3 DAMPs and APAP hepatotoxicity 
The sterile inflammatory response after APAP overdose requires the release of DAMPs. 
Previous studies reported measurement of DAMPs including HMGB1, heat shock 
proteins, and DNA fragments in plasma of APAP-treated animals (Antoine et al., 2009, 
2010; Jahr et al., 2001; Martin-Murphy et al., 2010; Scaffidi et al., 2002). In the case of 
HMGB1, it was shown that a hypo-acetylated form is passively released by necrotic 
cells and can be used similar to keratin-18 as a biomarker of necrosis (Antoine et al., 
2009). In addition, a hyper-acetylated form of HMGB1 can be actively secreted by 
macrophages or monocytes (Bonaldi et al., 2003) and thus can represent a potential 
biomarker of inflammation (Antoine et al., 2009). Consistent with these previous 
observations, we found a substantial increase in nuclear DNA fragments, in plasma 
keratin-18 and in total HMGB1 levels after APAP treatment. However, the increase in 
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these plasma biomarkers of hepatic necrosis was neither affected by aspirin treatment 
nor by deficiency of inflammasome genes. Furthermore, the levels of hypo-acetylated 
HMGB1 (necrosis) and hyper-acetylated HMGB1 (inflammation) when determined by 
mass spectrometry were not modulated in the knockout mice or affected by aspirin 
treatment. These data are consistent with both the histology data and other markers 
(ALT) and demonstrate that the overall APAP-induced cell necrosis in these livers is the 
same in all groups. Moreover, the similar release of DAMPs in all groups is consistent 
with the similar overall induction of pro-inflammatory cytokine and chemokine genes and 
recruitment of neutrophils into the livers. Thus, despite the minor effect of IL-1β 
processing caused by the activation of the Nalp3 inflammasome (Imaeda et al., 2009; 
Chapter 2), the overall inflammatory response after APAP overdose is not dependent on 
the Nalp3 inflammasome and does not impact on the overall extent of observed toxicity.  
The data presented in this manuscript are fully consistent with a previous study 
(Chapter 2) showing that IL-1β formation and processing by the inflammasome has no 
relevant impact on the degree of APAP hepatotoxicity in mice. However, this is not 
consistent with the results and conclusions presented by Imaeda et al. (2009) and in 
part by Chen et al. (2007). The conclusions presented herein are based on data from 
three independent research groups, that the activation of the Nalp3 inflammasome does 
not play a significant role in the pathogenesis of experimental APAP hepatotoxicity. We 
have extended the original investigations reporting a critical role for the Nalp3 
inflammasome in APAP toxicity by inclusion of the characterization of the inflammatory 
response, a more extended quantification of cell death and associated biomarker 
release. Each of these factors was not altered between the genetic or pharmacological 
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manipulation of the inflammasome and the overall degree of toxicity. It is important to 
point out only low levels of IL-1β produced in the APAP-treated mice could be detected 
in all studies, but the evidence for a functional consequence of such cytokine release 
was inconsistent. There is no obvious explanation for these discrepancies. However, 
there are minor differences in the experimental design that need to be considered 
between our present study and the experiments reported by Imaeda et al. (2009). For 
the experiments with the knock-out mice, we used our standard dose of 300 mg/kg 
compared to 500 mg/kg by Imaeda et al., (2009). However, the aspirin study was 
performed administering the same dose of APAP as used by Imaeda et al. (2009) but 
still resulted in no protection. In addition, we terminated our experiments at 24 h 
compared to 12 h in the Imaeda study. It appears unlikely that there could be protection 
at earlier time points that is lost at later times given the fact that inflammatory liver injury 
generally occurs at later time points. Lastly, the sources of the mice used in these 
studies were different. Although it cannot be completely ruled out that the different 
sources of mice may have affected the results, the fact that our results with the various 
knock-out mice are fully consistent with pharmacological interventions (caspase 
inhibitors, aspirin) and additional manipulations (injection of pharmacological doses of 
IL-1β) (Chapter 2) as well as a battery of studies on the role of neutrophils in the 
pathogenesis of APAP hepatoxicity in rats and various mouse strains (Bauer et al., 
2000; Cover et al., 2006; James et al., 2003; Lawson et al., 2000; Welty et al., 1993), 
gives us confidence in the general applicability of our data and conclusions. Although, 
an important aspect of the present study was to demonstrate that the pharmacological 
manipulations used for investigation of the inflammasone did not alter the metabolic 
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activation of APAP to its toxic metabolite. In addition to unrecognized effects on drug 
metabolism, pharmacological interventions and genetic manipulations can trigger stress 
responses with expression of protective genes or cause compensatory responses that 
may affect APAP toxicity (Jaeschke et al., 2011).  
It is well recognized that an inflammatory response after an acute tissue injury can have 
multiple opposing effects (Bulkley and Roberts, 1974). Although inflammation may 
enhance tissue injury under certain circumstances, the recruited neutrophils and 
especially macrophages are critical for removal of necrotic cell debris and promotion of 
tissue repair. Our data provide further support that in the APAP model, inflammatory 
cells do not directly cause liver damage. However, there is evidence to indicate that 
suppressing the late inflammatory response delays liver regeneration (Dambach et al., 
2002; Holt et al., 2008).    
3.5.4 Summary 
Our data clearly demonstrated that APAP overdose caused substantial liver injury, 
release of DAMPs and a sterile inflammatory response. However, mice deficient in 
components of the Nalp3 inflammasome (ASC-/-, Nalp3-/- and caspase1-/-) or wild type 
mice treated with aspirin showed very similar responses to APAP as wild type animals 
treated with APAP alone. These data are consistent with previous pharmacological 
approaches to inhibit caspase-1, with data obtained in IL-1 receptor-/- mice, and with 
the lack of effects when pharmacological doses of IL-1β were administered (Chapter 2). 
All these data together strongly support the conclusion that the minor endogenous 
formation of IL-1β and the activation of the Nalp3 inflammasome has no relevant impact 
on APAP hepatotoxicity and therefore the Nalp3 inflammasome  may not be a viable 
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therapeutic target to treat APAP overdose. Caution must therefore be exercised in 
translating this concept to man with respect to aspirin acting as a hepatoprotective 
agent against APAP-induced liver injury.    
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Chapter 4 
Role of CD18 and neutrophil priming during APAP overdose 
 
 
 
 
 
 
 
 
Reproduced from: 
Liver International, 30(9):1280-1292, Acetaminophen-induced hepatic neutrophil 
accumulation and inflammatory liver injury in CD18-deficient mice, 2010, with 
permission from Wiley. 
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4.1 Abstract 
Acetaminophen (APAP) hepatotoxicity is currently the most frequent cause of acute 
liver failure in the US and many European countries. Although intracellular signaling 
mechanisms are critical for hepatocellular injury, a contribution of inflammatory cells, 
especially neutrophils, has been suggested. However, conflicting results were obtained 
when using immunological intervention strategies. The role of neutrophils was 
investigated using a CD18-deficient mouse model. Treatment of C57Bl/6 wild type mice 
with 300 mg/kg APAP resulted in severe liver cell necrosis at 12 and 24 h. This injury 
was accompanied by formation of cytokines and chemokines and accumulation of 
neutrophils in the liver. However, there was no difference in the inflammatory response 
or liver injury in CD18-deficient mice compared to wild type animals. In contrast to 
treatment with endotoxin, no upregulation of CD11b or priming for reactive oxygen was 
observed on neutrophils isolated from the peripheral blood or the liver after APAP 
administration. Furthermore, animals treated with endotoxin 3 h after APAP experienced 
an exaggerated inflammatory response as indicated by substantially higher cytokine 
and chemokine formation and twice the number of neutrophils in the liver. However, 
liver injury in the two-hit model was the same as with APAP alone. Our data do not 
support the hypothesis that neutrophils contribute to APAP hepatotoxicity or that a 
neutrophil-mediated injury phase could be provoked by a second, pro-inflammatory hit. 
Thus, APAP-induced liver injury in mice is dominated by intracellular mechanisms of cell 
death rather than by neutrophilic inflammation. 
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4.2 Introduction 
Acetaminophen (APAP) overdose is currently the most frequent cause of acute liver 
failure in the US and many other countries (Lee, 2004; Larson et al., 2005). The 
mechanisms of cell injury induced by APAP have been extensively studied in vivo and 
in primary cultured hepatocytes during the last several decades. The main intracellular 
events critical for hepatotoxicty include the formation of a reactive metabolite, which 
causes glutathione depletion and covalent protein modifications, mitochondrial 
dysfunction and oxidant stress, peroxynitrite formation, and nuclear DNA fragmentation 
by mitochondrial-derived endonuclease G and apoptosis-inducing factor (Nelson, 1990; 
Jaeschke et al., 2003; Jaeschke and Bajt, 2006). Ultimately these events, especially the 
oxidant stress and peroxynitrite formation in the mitochondria (Cover et al., 2005), 
trigger the opening of the membrane permeability transition pore and the collapse of the 
mitochondrial membrane potential leading to necrotic cell death (Kon et al., 2004; Gujral 
et al., 2002).  
In addition to the intracellular signaling events, a potential contribution of inflammatory 
cells to the overall injury after APAP overdose came into focus during the last decade 
(Jaeschke, 2005; Liu and Kaplowitz, 2006). During an inflammatory response, 
neutrophils can accumulate in sinusoids, extravasate and kill stressed hepatocytes 
mainly through reactive oxygen formation (Jaeschke 2006). It is well documented that 
liver injury can be exacerbated by neutrophils during ischemia-reperfusion injury 
(Jaeschke et al., 1990), endotoxemia (Jaeschke et al., 1991), alcoholic hepatitis 
(Bautista 1997; Ramaiah and Jaeschke 2007), and obstructive cholestasis (Gujral et al., 
2003) as well as during drug- and chemical-induced hepatotoxicity by α- 
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naphthylisothiocyanate (Dahm et al., 1991; Kodali et al., 2006), halothane (You et al., 
2006) and concanavalin A (Bonder et al., 2004). However, the role of neutrophils in 
acetaminophen hepatotoxicity is controversially discussed (Jaeschke 2008). Evidence 
for (Smith et al., 1998; Liu et al., 2006; Ishida et al., 2006) and against (Lawson et al., 
2000; Bauer et al., 2000; Cover et al., 2006) a contribution of neutrophils to the overall 
injury has been presented. 
More recent reports show that danger-associated molecular patterns (DAMPs) released 
from necrotic hepatocytes after APAP overdose can activate toll-like receptors on 
Kupffer cells and induce the formation of inflammatory mediators through the 
inflammasome (Chen et al., 2007; Imaeda et al., 2009; Chen et al., 2009). The 
implication is again that inflammatory cytokines such as interleukin-1β promote a 
neutrophil-mediated aggravation of the initial injury (Chen et al., 2007; Imaeda et al., 
2009; Chen et al., 2009). A problem with the previous studies evaluating a potential 
effect of neutrophils on APAP hepatotoxicity was the use of immunological agents, i.e. 
neutropenia-inducing antibodies, which resulted in conflicting results (Smith et al., 1998; 
Liu et al., 2006; Bauer et al., 2000; Cover et al., 2006). To avoid these issues, we 
applied a genetic approach by using mice deficient in the β-chain (CD18) of β2 integrins 
(CD11/CD18). β2 integrins on neutrophils are critical for their adhesion to receptors on 
endothelial cells and hepatocytes as well as the adherence-dependent generation of 
reactive oxygen species (Smith, 1993). Consequently, neutrophil accumulation during 
peritonitis was drastically reduced in CD18-deficient mice (Wilson et al., 1993). In 
addition, we showed previously in these mice impaired extravasation of neutrophils and 
reduced reactive oxygen formation in the liver resulting in less inflammatory cell injury 
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during obstructive cholestasis (Gujral et al., 2003). Based on these data, we tested the 
hypothesis that if neutrophils play a relevant role in the progression of APAP 
hepatotoxicity, CD18-deficient mice should be at least partially protected. 
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4.3 Materials and Methods 
4.3.1 
Animals. Male CD18-deficient mice (B6.129S7-Itgb2tm1Bay/J; Stock number: 002128), 
which are backcrossed to a C57BL/6J background and their age-matched control 
littermates (C57BL/6J) with an average weight of 18 to 20 g were purchased from 
Jackson Laboratory (Bar Harbor, Maine). All animals were housed in an environmentally 
controlled room with 12 h light/dark cycle and allowed free access to food (# 8604 
Teklad Rodent, Harlan, Indianapolis, IN) and water.  The experimental protocols were 
approved by the Institutional Animal Care and Use Committee of University of Kansas 
Medical Center and followed the criteria of the National Research Council for the care 
and use of laboratory animals in research.  
4.3.2 
Experimental design.  All chemicals were purchased from Sigma Chemical Co. (St. 
Louis, MO) unless stated otherwise. Mice were intraperitoneally injected with 300 mg/kg 
APAP (dissolved in warm saline) after overnight fasting. The animals were killed 12 or 
24 h after APAP treatment, blood was withdrawn from the vena cava into a heparinized 
syringe for measurement of alanine aminotransferase (ALT) activities (Kinetic Test Kit 
68-B, (Biotron Diagnostics, Inc., Hernet, CA) and cytokine levels. The liver was removed 
and was rinsed in saline; liver sections were fixed in 10% phosphate buffered formalin 
for histological analyses. The remaining liver was snap-frozen in liquid nitrogen and 
stored at -80 C. In additional experiments, groups of animals were first treated with 300 
mg/kg APAP and 3 h later either with saline (10 ml/kg) or 100 μg/kg Salmonella abortus 
equi endotoxin (ET) (i.p.). As positive controls for neutrophil-mediated liver injury, a few 
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animals were subjected to common bile duct ligation (BDL) for 2 days as described in 
detail (Gujral et al., 2003).  
 4.3.3 
Histology. Formalin-fixed tissue samples were embedded in paraffin and 5 m sections 
were cut. Sections were stained with hematoxylin and eosin (H&E) for blinded 
evaluation of the areas of necrosis by the pathologist. The percent of necrosis was 
estimated by evaluating the number of microscopic fields with necrosis compared to the 
entire cross section. Additional sections were stained for neutrophils. Endogenous 
peroxidase was suppressed with peroxidase suppressor (Thermo, Waltham, MA). 
Tissue was blocked with serum free blocker (Dako, Carpinteria, CA). Trypsin antigen 
retrieval was performed (Abcam, Cambridge, MA). Anti-mouse neutrophil allotypic 
marker antibody (AbD Serotec, Raleigh, NC) was incubated for 1 hour at room 
temperature.  Secondary antibody coupled with biotin was then added (Vector, 
Burlingame, CA) followed by streptavadin-HRP conjugate (Vector).  DAB substrate was 
used (Dako) and then counterstained with hematoxylin (Sigma). Positively stained cells 
consistent with neutrophil morphology were quantified in randomly selected high power 
fields (HPF, x400). 
4.3.4 
mRNA expression. Quantification of mRNA expression of several cytokines and 
chemokines was performed by real-time PCR (RT-PCR) analysis as previously 
described (Bajt et al., 2008). cDNA was generated by reverse transcription of total RNA 
by M-MLV reverse transcriptase in the presence of random primers (Invitrogen, 
Carlsbad, CA).  Forward and reverse primers for the genes were designed using Primer 
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Express software (Applied Biosystems, Foster City, CA). After normalization of cDNA 
concentrations, SYBR green PCR Master Mix (Applied Biosystems) was used for real-
time PCR analysis. The relative differences in expression between groups were 
expressed using cycle time (Ct) values generated by the ABI 7900 instrument (Applied 
Biosystems). All genes evaluated were first normalized to β-actin and then expressed 
as a fold increase relative to control which was arbitrarily set as 1.0. Calculations are 
made by assuming one cycle is equivalent to a two-fold difference in copy number 
which is the 2^(-ddCt) formula. 
4.3.5 
Plasma cytokine measurements. Quantification of cytokines was performed in plasma 
by the Bio-Plex bead-based multiplex assay following the kit instructions (Bio-Rad 
Laboratories, Hercules, CA) and analyzed on the Bio-Plex 200 instrument (Bio-Rad). 
4.3.6 
Isolation of hepatic non-parenchymal cells. The procedure was adapted from a method 
decribed by Watanabe et al. (Watanabe et al., 1992). Under isoflurane anesthesia mice 
were exsanguinated from the caudal vena cava into heparinized tubes and the blood 
was placed on ice; the liver was then perfused through the portal vein with 1.0 mL ice-
cold Dulbecco’s PBS.  The liver was immediately excised, placed in ice-cold PBS and 
minced with scissors.  The tissue was then pressed through a 200-gauge stainless steel 
mesh into a 50mL conical tube. The cell suspension was centrifuged at 50 x g for 2 
minutes to remove hepatocytes and large debris. The supernatant containing non-
parenchymal cells was then centrifuged at 350 x g for 5 minutes and cells were washed 
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twice in a 15 mL conical bottom tube. Viable, nucleated cells were counted by trypan 
blue exclusion and brought to a uniform cell density.  
4.3.7 
Flow Cytometric Analysis of CD11b Expression and Reactive Oxygen Formation. 
CD11b/Gr-1 staining (Bajt et al., 2001; Daley et al., 2008). 5µg Fc receptor (FcR) 
blocking antibody (BioLegend, San Diego, CA) diluted in 100µL 0.1% BSA in PBS was 
added to 100µL non-parenchymal cell suspension for 20 minutes on ice. To 50µL whole 
blood or 200µL FcR-blocked hepatic non-parenchymal cells, saturating concentrations 
of PE-Cy5-labeled-anti-Gr-1 (BioLegend) and PE-labeled-anti-CD11b (BioLegend) 
diluted in 0.1% BSA in PBS were added. Tubes were incubated in the dark, on ice for 
30 minutes. After washing with 0.1% BSA, red blood cells were lysed using RBC lysing 
solution (0.155 M NH4Cl, 10 mM KHCO3, 0.1 mM EDTA). Pellets were washed three 
times with 0.1% BSA then fixed with 2.5% buffered formalin. Samples were measured 
on the FACSCalibur (BD, Franklin Lakes, NJ). We gated on the Gr-1high cells, which is 
also the only Ly6G-positive population (Daley et al., 2008). Cells, which are Gr-1high 
were identified as neutrophils by cell morphology. Other leukocytes are either Gr-
1intermediate (mainly monocytes and eosinophils) or Gr-1negative (monocytes and 
lymphocytes) (Daley et al., 2008). The data were analyzed using the BD FACSDiva 6.0 
software. 
Reactive Oxygen Production (Emmendorffer et al., 1990; Smith and Weidemann, 1993). 
To 50µL whole blood or 100µL hepatic non-parenchymal cells, 10 µM 
diphenyleneiodonium or vehicle (0.1% DMSO) was added to each tube for 20 minutes. 
2 µM phorbol 12-myristate 13-acetate (PMA) or saline was added and incubated for 10 
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minutes at 37ºC. 4 µM dihydrorhodamine-123 was added and incubated for 10 minutes 
at 37ºC. Ice-cold 0.1% BSA in PBS was added and pellets were washed. The non-
parenchymal cell suspension was blocked with FcR blocking antibody (BioLegend) as 
previously described and cells were stained with saturating concentrations of PE-Cy5-
labeled-anti-Gr-1 (BioLegend) diluted in 0.1% BSA. Tubes were incubated in the dark, 
on ice for 30 minutes. After washing with 0.1% BSA, red blood cells were lysed using 
RBC lysing solution. Pellets were washed three times with 0.1% BSA then fixed with 
2.5% buffered formalin. Samples were measured on the FACSCalibur (BD) and the 
data were analyzed using the BD FACSDiva 6.0 software. 
4.3.8 
Statistics.  All results were expressed as mean  SE. Comparisons between 
multiple groups were performed with one-way ANOVA or, where appropriate, by 
two-way ANOVA, followed by a post hoc Bonferroni test. If the data were not 
normally distributed, we used the Kruskal-Wallis Test (nonparametric ANOVA) 
followed by Dunn’s Multiple Comparisons Test. P < 0.05 was considered significant. 
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4.4 Results 
4.4.1  Liver injury and oxidant stress in C57Bl/6 and CD18-deficent mice 
Administration of 300 mg/kg APAP to C57Bl/6 and CD18-deficient mice resulted in 
severe liver injury at 12 and 24 h as indicated by the highly elevated plasma ALT 
activities (4.4.1.1A) and the extensive centrilobular necrosis (4.4.1.1B,C). Blinded 
quantification of cell death revealed that approximately 50% of all hepatocytes were 
necrotic in wild type and CD18-deficient animals at 24 h (4.4.1.1B). Hepatic 
glutathione (GSH+GSSG), which is depleted by >90% during the first hour after 
APAP, was only partially recovered at 12 h but reached baseline values at 24 h 
(4.4.1.2A). APAP induced a significant oxidant stress as indicated by the increase 
of hepatic GSSG values and the increase of the GSSG-to-GSH ratio (4.4.1.2B,C).  
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4.4.1.1 
 
Acetaminophen-induced liver injury in C57Bl/6 wild type and CD18-deficient mice. 
Animals were treated with 300 mg/kg APAP and plasma ALT was measured at 12 h and 
at 24 h (A) and the area of necrosis was quantified at 24 h (B). Data represent means ± 
SE of n = 5 animals per group. *P<0.05 (compared to untreated controls).  C. 
Representative H&E-stained liver sections of animals treated for 12 h and 24 h with 300 
mg/kg APAP (x50 for all panels).  
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4.4.1.2 
 
Hepatic content of total GSH (GSH + GSSG) (Panel A) and GSSG (Panel B) were 
measured in untreated controls (C) and in C57Bl/6 wild type and CD18-deficient 
mice treated with 300 mg/kg APAP for 12 h or 24 h. In addition, the GSSG-to-GSH 
ratio (Panel C) was calculated from each animal. Data represent means ± SE of n = 
5 animals per group. *P<0.05 (compared to respective control)   
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4.4.2  Liver neutrophil recruitment in C57Bl/6 and CD18-deficent mice 
following APAP or bile duct ligation 
Immunohistochemical staining for neutrophils showed extensive accumulation of 
these leukocytes in the liver at 12 h and a substantial further increase at 24 h 
(4.4.2.1A). However, despite the fairly high numbers of neutrophils around the area 
of necrosis after APAP (4.4.2.1B), animals subjected to bile duct ligation, where 
neutrophils play a critical role in liver injury (Gujral et al., 2003; Gujral et al., 2004), 
showed a substantially higher accumulation of neutrophils around the bile infarcts 
(necrotic foci) (4.4.2.1B). Overall, the APAP data are consistent with previous 
findings regarding the degree of injury, oxidant stress and inflammation in this 
model (Knight et al., 2001). Treatment of CD18-deficient mice with APAP resulted 
in similar liver injury as compared to wild type animals as judged by both plasma 
ALT activities and histology (4.4.1.1) and showed similar oxidant stress (4.4.1.2) 
and hepatic neutrophil accumulation (4.4.2.1).  
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4.4.2.1 
 
Hepatic neutrophil accumulation after APAP treatment in C57Bl/6 wild type and CD18-
deficient mice. A. Neutrophil numbers were quantified in 15 randomly selected high 
power fields (HPF; x400). Data represent means ± SE of n = 5 animals per group.  
*P<0.05 (compared to untreated controls). B. Comparison of neutrophil accumulation in 
an area of necrosis 12 h after 300 mg/kg APAP or 2 days after common bile duct 
ligation (BDL). (x200). Red arrows highlight selected neutrophils in sinusoids and on the 
periphery of necrosis in the APAP-treated liver. 
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4.4.3 Inflammatory response in C57Bl/6 and CD18-deficient mice 
To evaluate pro-inflammatory mediator formation, the hepatic mRNA of selected 
cytokines and chemokines were measured (4.4.3.1). A variable but significant 
increase above untreated controls was found for all cytokines/chemokines at 12 h 
and at 24 h after APAP. Consistent with these findings, plasma protein levels of 
most of these cytokines and chemokines were significantly increased at both time 
points (4.4.3.2). However, the increase was generally moderate and limited to levels 
between 2-fold to less than 10-fold above baselines. Most importantly, no significant 
difference in mRNA or serum protein levels of any cytokine or chemokine between 
wild type and CD18-deficient animals was observed (except the 12 h plasma TNF- 
levels). These data support the conclusion that a neutrophilic inflammatory 
response occurs early after the APAP-induced liver injury. However, animals with a 
deficiency in CD18 develop the identical degree of injury after APAP overdose 
suggesting that neutrophils do not play a critical role in the pathophysiology. 
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4.4.3.1
 
Hepatic cytokine/chemokine mRNA levels were measured 12 and 24 h after 
administration of 300 mg/kg acetaminophen (APAP) in C56Bl/6 wild type animals 
and in CD18-deficient mice. mRNA levels are expressed as the cytokine mRNA-to-
β-actin mRNA ratio. The values of untreated controls were set as 1 and the fold 
change of the APAP-treated animals was calculated. Data represent means ± SE of 
n = 6-7 animals per group. All cytokines and chemokines were significantly elevated 
over control (P<0.05) however differences between genotypes could be observed.   
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4.4.3.2
 
Plasma cytokine and chemokine levels after acetaminophen overdose in C57Bl/6 wild 
type and CD18-deficient mice. Animals were treated with 300 mg/kg APAP and plasma 
cytokine/chemokine levels were measured at 12 h and at 24 h after APAP using the 
Bioplex system. Data represent means ± SE of n = 5 animals per group. *P<0.05 
(compared to untreated controls). #P<0.05 (compared to wild type animals). 
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4.4.4 Characterization of Neutrophils after APAP overdose 
In order to further characterize a potential neutrophil priming or activation after 
APAP, the surface expression of Mac-1 (CD11b/CD18) and the capacity for the 
formation of reactive oxygen species (ROS) was determined in peripheral 
neutrophils (4.4.4.1) and in liver neutrophils (4.4.4.2) at 6 h after 300 mg/kg APAP. 
Upregulation of Mac-1 and priming for reactive oxygen formation of neutrophils is a 
hallmark of all models where neutrophils actively contribute to liver injury (Gujral et 
al., 2003; Bajt et al., 2001; Jaeschke et al., 1993). Despite significant injury at 6 h 
(ALT: 2840 ± 300 U/L; n=5), ROS formation and the expression of Mac-1 on 
peripheral neutrophils (4.4.4.1) and from hepatic neutrophils (4.4.4.2) from APAP-
treated animals were similar compared to cells obtained from untreated controls. As 
a positive control experiment, animals were treated with 100 µg/kg of endotoxin. 
Peripheral blood and hepatic neutrophils were evaluated at 1.5 h. The well-known 
cytokine response after endotoxin caused a 2.6-fold (2.0-fold) increase in ROS 
formation and a 25-fold (7.5-fold) increase in Mac-1 expression on peripheral 
(hepatic) neutrophils (4.4.4.1; 4.4.4.2). The quantitatively slightly lower activation of 
the hepatic neutrophils compared to the peripheral neutrophils may be due to the 
increased stress of isolating the cells from the liver. However, most importantly, the 
data obtained from peripheral neutrophils closely reflects the activation status of 
liver neutrophils. Measurements of blood and liver neutrophils in CD18-deficient 
mice showed similar ROS formation as obtained in wild type animals (data not 
shown). The reason for this is the use of PMA as stimulant. PMA directly activates 
protein kinase C intracellularly and does not depend on surface receptors. As 
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expected (Gujral et al., 2003), CD11b expression was substantially lower in CD18-
deficient samples compared to wild type (data not shown).                
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4.4.4.1 
 
Continued to following page. 
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4.4.4.1 (continued) 
 
Reactive oxygen species (ROS) priming and CD11b expression on peripheral 
neutrophils. C57Bl/6 mice (n=4 per group) were treated with 20 ml saline/kg for 6 hours, 
100 µg endotoxin/kg for 90 minutes or 300 mg APAP/kg for six hours. A. To determine 
reactive oxygen species (ROS) priming, mice were treated with APAP or endotoxin in 
vivo then whole blood was stimulated ex vivo with PMA. Upon PMA-induced ROS 
production DHR-123 is converted to R-123 and quantified in neutrophils by flow 
cytometry. In addition, immediately after in vivo stimulation with APAP or endotoxin 
whole blood was stained for CD11b surface expression and neutrophils were analyzed 
by flow cytometry. The Gr-1high cell population consists of neutrophils. Representative 
ROS or CD11b histograms or mean fluorescence intensities (B) for saline, the positive 
control endotoxin, and APAP are shown. *P<0.05 (compared to saline controls) 
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4.4.4.2 
 
Continued to following page. 
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4.4.4.2 (continued) 
 
Reactive oxygen species (ROS) priming and CD11b expression on liver accumulated 
neutrophils. C57Bl/6 mice (n=4 per group) were treated with 20 ml saline/kg for 6 hours, 
100 µg endotoxin/kg for 90 minutes or 300 mg APAP/kg for six hours. A. To determine 
reactive oxygen species (ROS) priming, mice were treated with APAP or endotoxin in 
vivo, non-parenchyma cells were isolated and then stimulated ex vivo with PMA. Upon 
PMA-induced ROS production DHR-123 is converted to R-123 and quantified in 
neutrophils by flow cytometry. In addition, immediately after in vivo stimulation with 
APAP or endotoxin, the isolated non-parenchymal cells were stained for CD11b surface 
expression and neutrophils were analyzed by flow cytometry. The Gr-1high cell 
population consists of neutrophils. Representative ROS or CD11b histograms or mean 
fluorescence intensities (B) for saline, the positive control endotoxin, and APAP are 
shown. *P<0.05 (compared to saline control) 
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4.4.5 Enhanced neutrophil recruitment with endotoxin after APAP overdose 
Because endotoxin caused a substantial activation of neutrophils, it was tested if 
treatment with endotoxin 3 h after APAP enhances neutrophil recruitment into the liver 
and potentially increases APAP-induced liver injury during the 24 h observation period. 
However, liver injury after the sequential administration of APAP and ET was the same 
as with APAP alone (4.4.5.1A,C) despite the doubling of the number of neutrophils in 
the liver (4.4.5.1B). Although the peaks of cytokine/chemokine formation after endotoxin 
occur well before the 24 h time point (Dorman et al., 2005), there was still a more than 
5-fold elevation of all mRNA levels and a 2- to 80-fold increase of plasma protein levels 
detectable at this late time (4.4.5.2). These data demonstrate that the additional 
treatment with endotoxin drastically enhanced the pro-inflammatory mediator formation 
and further promoted hepatic neutrophil accumulation. However, despite this substantial 
boost of the inflammatory response, liver injury was not different from injury with APAP 
alone (4.4.5.1). 
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4.4.5.1 
 
Effect of endotoxin treatment on acetaminophen-induced liver injury. Animals were first 
treated with 300 mg/kg APAP and 3 h later either with saline (10 ml/kg) or 100 μg/kg 
endotoxin (ET) (i.p.). Plasma ALT activities (A) and the number of liver accumulating 
neutrophils (B) were measured at 24 h. Data represent means ± SE of n = 5 animals per 
group. *P<0.05 (compared to untreated controls). #P<0.05 (compared to APAP alone).  
C. Representative H&E-stained liver sections (x50) and neutrophil staining (x100) of 
animals treated for 24 h with 300 mg/kg APAP alone or in combination with endotoxin. 
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4.4.5.2 
 
Plasma cytokine/chemokine concentrations and hepatic mRNA levels were measured 
24 h after administration of 300 mg/kg acetaminophen (APAP). Some animals were 
additionally treated with 100 µg/kg endotoxin (ET) at 3 h after APAP. mRNA levels are 
expressed as the cytokine mRNA-to-β-actin mRNA ratio. The values of untreated 
controls were set as 1 and the fold change of the APAP-treated animals was calculated. 
Data represent means ± SE of n = 4-5 animals per group. *P<0.05 (compared to APAP 
alone)   
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4.5 Discussion 
The main objective of this investigation was to test in a model with genetic deficiency of 
neutrophil function if these phagocytes are sufficiently activated and receive the 
appropriate signals during APAP overdose to further increase liver injury. This approach 
was necessary because previous attempts to evaluate the role of neutrophils in APAP 
hepatotoxicity yielded conflicting results due to the use of immunological intervention 
strategies, i.e. neutropenia-inducing antibodies (Liu et al., 2006; Ishida et al., 2006; 
Cover et al., 2006). The problem with this approach is that treatment with such an 
antibody results in the accumulation of antibody-tagged neutrophils in sinusoids. During 
the 24 h pretreatment time used in experiments that showed a protection against APAP 
toxicity (Liu et al., 2006; Ishida et al., 2006), Kupffer cells remove these inactivated 
neutrophils by phagocytosis, which causes the activation of Kupffer cells (Bautista et al., 
1994). Cytokines produced by these phagocytes act on hepatocytes and induce a 
number of genes, e.g., metallothionein, heme oxygenase-1 and others, some of which 
have been shown to protect against APAP overdose (Jaeschke and Liu, 2007). 
Although these findings cannot rule out that the protective effect with pretreatment of a 
neutropenia-inducing antibody was caused by the elimination of neutrophils, there are at 
least serious concerns that the induction of hepatoprotective genes (preconditioning 
effect) was at least in part if not completely responsible for the reduced injury after 
APAP. Our current experiments with CD18-deficient mice, which showed no protection 
against APAP hepatotoxicity, strongly support the hypothesis that neutrophils are not 
involved in the injury process in mice. In addition, the fact that endotoxin, which 
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dramatically exaggerated the inflammatory response, did not affect the overall injury 
further supports this conclusion.  
Members of β2 integrin family, especially CD11a/CD18 and CD11b/CD18, are essential 
for firm adhesion of neutrophils to endothelial cells via binding to intercellular adhesion 
molecule-1 (ICAM-1), for their extravasation and for the adhesion to potential target 
cells, where a long-lasting, adhesion-dependent oxidant stress can be triggered (Smith, 
1993). The neutrophil-dependent oxidant stress is responsible for target cell killing 
(Entman et al., 1992). In contrast to this general mechanism of neutrophil adhesion, 
which applies mainly to postcapillary venules in a variety of vascular beds, in the liver, 
the pathophysiologically most relevant accumulation of neutrophils occurs in sinusoids 
(Chosay et al., 1997). Because of the low shear stress in sinusoids, selectins, CD18 or 
ICAM-1 are not necessary for hepatic neutrophil recruitment (Wong et al., 1997; 
Jaeschke et al., 1996). If the sinusoidal endothelium is intact, blocking these adhesion 
molecules with an antibody or deficiency of CD18 or ICAM-1 does not prevent 
neutrophil accumulation in sinusoids (Bautista, 1997; Jaeschke et al., 1996; Essani et 
al., 1995). An effect on neutrophil numbers in the liver can only be seen after longer 
time period as documented in CD18- and ICAM-1-deficient animals 3 days after bile 
duct ligation (Gujral et al., 2003; Gujral et al., 2004). This reflects the reduced 
inflammatory response due to the reduced tissue injury rather than a direct inhibition of 
neutrophil adhesion (Gujral et al., 2003; Gujral et al., 2004). However, blocking CD18 
inhibits the extravasation of neutrophils and prevents the neutrophil-induced oxidant 
stress and injury (Jaeschke et al., 1991; Gujral et al., 2003; Gujral et al., 2004; Essani et 
al., 1995). Even if the endothelium is severely damaged and does not provide a relevant 
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barrier for neutrophils, e.g. during hepatic ischemia-reperfusion injury, CD18 antibodies 
are still highly effective due to the attenuation of the adhesion-dependent oxidant stress 
(Jaeschke et al., 1991; Jaeschke et al., 1993). In all models where neutrophils increase 
liver injury it was consistently shown that a neutrophil component was evident during the 
first 24 h (Jaeschke et al., 1990; Jaeschke et al., 1991; Dahm et al., 1991; Dold et al., 
2009). Taken together, if neutrophils contributed to the APAP hepatotoxicity, a 
beneficial effect should have been observed in CD18-deficient mice during the first 24 h 
after APAP administration. However, despite the mild inflammatory response as judged 
by cytokine and chemokine formation and the accumulation of neutrophils in the liver, 
there was no evidence that any of these effects are reduced in CD18-deficient animals. 
Because neutrophil-induced cell killing in the liver also requires reactive oxygen 
(Jaeschke, 2006), these data are consistent with previous reports showing that 
inhibitors of NADPH oxidase (Cover et al., 2006) or genetic deficiency in the function of 
this enzyme (James et al., 2003) do not protect against APAP-mediated liver injury. The 
lack of priming for reactive oxygen formation in peripheral and in liver accumulated 
neutrophils is also in agreement with this finding. Nevertheless, the fact that neutrophil 
accumulation is moderate, occurs mainly after the onset of severe cell injury (Lawson et 
al., 2000; Cover et al., 2006) and can be reduced by antibodies against DAMPs, e.g. 
high mobility group box proteins (Chen et al., 2009; Scaffidi et al., 2002), suggest this is 
a classical scenario of a sterile inflammatory response.  
Because it appears that the modest activation of neutrophils during APAP hepatotoxicity 
is insufficient to trigger an active attack of these phagocytes, a more aggressive 
inflammatory response was induced by treatment with endotoxin several hours after 
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APAP. This schedule was chosen to mimic a realistic scenario of massive cytokine 
formation and neutrophil activation at the time of APAP-induced injury. Previously, we 
could show that administration of a low dose of endotoxin after hepatic ischemia-
reperfusion drastically increased the inflammatory response including neutrophil 
activation and the neutrophil-mediated injury (Liu et al., 1994; Liu et al., 1995). In this 
combination model of two insults, even the delayed treatment with an antibody against 
CD18 was highly effective in reducing reperfusion injury (Liu et al., 1995). Although the 
enhanced cytokine and chemokine formation after endotoxin recruited substantially 
more activated neutrophils into the liver after APAP overdose, no increased injury was 
detected. These results may be surprising, however, they are consistent with our 
mechanistic understanding of neutrophil-mediated liver injury (Jaeschke, 2006; 
Ramaiah  and Jaeschke, 2007; Jaeschke and Hasegawa, 2006). Various cytokines 
(TNF-, IL-1), chemokines (IL-8, MIP-2, KC), activated complement factors (C5a) and 
other proinflammatory mediators can individually and in combination activate 
neutrophils to various degrees and induce their accumulation in sinusoids (Bajt et al., 
2001; Chosay et al., 1997; Essani et al., 1995). This process does not require CD18 
(Jaeschke et al., 1996), hence CD18-deficient mice did not show less sinusoidal 
neutrophil accumulation. In addition, primed neutrophils in sinusoids do not randomly 
cause liver injury (Chosay et al., 1997). For neutrophils to actually participate in killing of 
larger cells such as hepatocytes, neutrophils need to extravasate and adhere to the 
target. This process requires CD18 and ICAM-1 (Jaeschke et al., 1991; Gujral et al., 
2003; Gujral et al., 2004; Essani et al., 1995). In addition, it requires a distress signal 
from the parenchyma that indicates to neutrophils located in the sinusoid a cell might be 
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dying and needs to be removed (Ramaiah and Jaeschke, 2007; Gujral et al., 2004b). 
The attack on the target involves an adherence-dependent oxidant stress (CD18-
dependent) and killing by reactive oxygen including hypochlorous acid (Jaeschke et al., 
1991, Gujral et al., 2003; Gujral et al., 2004a; Gujral et al., 2004b; Jaeschke et al., 
1993). Whether or not such an attack actually enhances liver injury depends on the 
initial insult. If the stress is mild and non-lethal, the stressed cell can trigger a neutrophil 
attack, which will kill the cell and therefore increase the injury. If the stress is already 
lethal by itself, e.g. APAP toxicity in hepatocytes, the accumulation and attack of 
neutrophils will have no impact on the overall injury. Thus, levels of cytokines and other 
pro-inflammatory mediators determine the degree of neutrophil activation and 
accumulation in sinusoids; the distress signal from injured cells determines the degree 
of extravasation and attack on hepatocytes. However, whether this makes a difference 
in the extent of liver damage is determined by the original stress or insult. Based on our 
data we can conclude that the intracellular signaling mechanisms induced by APAP in 
hepatocytes determine whether or not a cell will die and the neutrophilic inflammatory 
response has no impact on the injury. However, this does not exclude a critical role of 
neutrophils and macrophages in the removal of cell debris and preparation for 
regeneration.  
In summary, our data documented severe liver injury after APAP overdose, which was 
accompanied by pro-inflammatory mediator formation and moderate hepatic neutrophil 
accumulation. However, animals with a deficiency of CD18, which has been shown to 
be critical for neutrophil-induced liver injury in a number of liver disease models, were 
not protected against APAP hepatotoxicity. In addition, stimulated cytokine formation 
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and enhanced hepatic recruitment of activated neutrophils did not enhance APAP-
induced liver injury. Together these data do not support the hypothesis that neutrophils 
contribute to APAP hepatotoxicity or that a neutrophil-mediated injury phase could be 
provoked by a second, pro-inflammatory hit. Thus, APAP-induced liver injury in mice is 
dominated by intracellular mechanisms of cell death rather than by neutrophilic 
inflammation. 
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Chapter 5 
Role of neutrophils and NADPH oxidase during APAP injury resolution 
 
 
 
 
 
 
 
 
 
 
 
121 
 
5.1 Abstract 
Acetaminophen (APAP) is a widely used antipyretic and analgesic drug (Tylenol®); 
overdose is the most frequent cause of acute liver failure in the US.  Following APAP-
overdose there is a robust inflammatory response triggered by the release of cellular 
contents from necrotic hepatocytes into systemic circulation.  This inflammatory 
response initiates the recruitment of neutrophils into the liver, followed by monocyte 
infiltration.  The primary mechanism by which phagocytes can exacerbate tissue injury 
is by the production and release of reactive oxygen species (ROS) generated by 
NADPH oxidase.  It has been demonstrated that neutrophils and resident liver 
macrophages do not contribute to APAP-induced liver injury but their role, and the role 
of NADPH oxidase, in injury resolution is unclear.  To investigate this, C57BL/6 mice 
were subjected to APAP-overdose and sacrificed at various times (24-72 h) during liver 
regeneration.  Neutrophils in the peripheral blood of these mice showed increasing 
activation status (CD11b expression and ROS priming) during and after the peak of 
injury but returned to baseline levels prior to complete injury resolution.  Hepatic 
sequestered neutrophils showed an increased and sustained CD11b expression, 
however at no time had enhanced ROS priming.  To confirm these findings, gp91phox-/- 
(NADPH oxidase defective) mice were subjected to APAP-overdose and displayed no 
alteration in injury resolution indicating phagocytic ROS is not essential for injury 
resolution.  Peripheral blood from human APAP-overdose patients also showed 
increased neutrophil activation status after the peak of liver injury.  These findings show 
similar neutrophil activation in peripheral blood of humans and mice which may be a 
critical event for host defense or injury resolution following APAP-overdose. 
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5.2 Introduction 
Acetaminophen (APAP) overdose is the leading cause of acute liver failure in the US, 
and can result in severe liver injury and potentially death.  The hepatotoxicity of APAP is 
initiated by metabolic conversion of APAP to the reactive metabolite N-acetyl-p-
benzoquinone imine (NAPQI).  This reactive metabolite results in glutathione (GSH) 
depletion and eventually causes adduction of cellular proteins which is the initiating 
event in toxicity (Jaeschke and Bajt, 2006).  Downstream of protein binding is 
mitochondrial dysfunction, increased oxidant stress, mitochondrial permeability 
transition pore (MPT) opening, DNA damage by endonucleases, and hepatocellular 
necrosis.  The massive cellular necrosis results in the release of damage associated 
molecular patterns (DAMPs) into systemic circulation; these DAMPs (including HMGB-
1, nuclear DNA, and numerous others) then triggers a sterile inflammatory response 
resulting in increase cytokine/chemokine formation and recruitment of innate immune 
cells into the liver.  In the mouse model neutrophils are initially recruited to the site of 
injury followed by monocytes/macrophages.  Previously it was believed that that this 
inflammatory response and neutrophil influx exacerbated the injury (Liu et al., 2006), but 
extensive evidence has been presented to the contrary (Cover et al., 2006; Lawson et 
al., 2000; Jaeschke and Liu, 2007; James et al. 2003; Ju et al., 2002; Chapters 2-4).   
Neutrophils are a first-line defense from pathogens and are essential for microbial 
phagocytosis and killing.  During APAP overdose this innate immune function is critical 
for host defense especially if the patient progresses toward fulminant hepatic failure 
(FHF).  It was reported that bacteremia occurs in up to one third of FHF patients and 
bacterial infection may be the cause of death for up to 20% of FHF patients (Wyke, 
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1987).  This link between progression of liver injury toward liver failure and innate 
immune function is of great interest; potentially this loss of host defense could be 
mediated by impaired synthesis of complement components, impaired phagocytosis of 
gut-derived bacteria by Kupffer cells, or multiple immune deficits which may or may not 
include neutrophils. 
Characterization of resident and infiltrating macrophages/monocytes has been 
performed in the mouse model of APAP overdose following the peak of injury, and it 
was demonstrated that the infiltrating monocyte/macrophage population is inherently 
anti-inflammatory and needed for injury resolution (Holt et al. 2008).  No 
characterization of neutrophils following the injury phase of APAP has been performed 
however, and for this reason the role of peripheral blood and hepatic-sequestered 
neutrophils beyond the injury phase of APAP has remained unclear.  In this study we 
determined the progression of neutrophil activation and hepatic accumulation in the 
mouse model.  In conjunction, we investigate if NADPH oxidase (phagocyte ROS) is 
critical for injury resolution following APAP overdose; it has already been shown that 
NADPH oxidase does not participate in injury (James et al., 2003).  Additionally we 
evaluated the activation status of human granulocytes in several APAP overdose 
patients and compared the activation status to what we observed in the better 
mechanistically understood mouse model. 
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5.3 Materials and Methods 
5.3.1 
Animals.  Male gp91phox-deficient (aka: Nox-2-/-, Cybb-/-, Phox-/-) mice (B6.129S-
Cybbtm1Din/J; Stock number: 002365) and C57BL/6J control mice (Stock number: 
000664) with an average weight of 18 to 20 g were purchased from Jackson Laboratory 
(Bar Harbor, Maine). All animals were housed in an environmentally controlled room 
with 12 h light/dark cycle and allowed free access to food (# 8604 Teklad Rodent, 
Harlan, Indianapolis, IN) and water.  The experimental protocols were approved by the 
Institutional Animal Care and Use Committee of University of Kansas Medical Center 
and followed the criteria of the National Research Council for the care and use of 
laboratory animals in research.  
5.3.2 
Experimental design. All chemicals were purchased from Sigma Chemical Co. (St. 
Louis, MO) unless stated otherwise.  Mice were intraperitoneally (i.p.) injected with 300 
mg/kg APAP (dissolved in warm saline) or saline vehicle after overnight fasting. The 
animals were sacrificed 6, 12, 24, 48 or 72 h after APAP treatment, blood was 
withdrawn from the vena cava into a heparinized syringe for measurement of alanine 
aminotransferase (ALT) activities (Pointe Scientific, Canton, MI) and flow cytometric 
analysis. The liver was removed and rinsed in saline; liver sections were fixed in 10% 
phosphate buffered formalin for histological analyses. The remaining liver was used for 
isolation of non-parenchymal cells (as described below). Additionally, as a positive 
control, some mice were treated (i.p.) with 100 μg/kg Salmonella abortus equi endotoxin 
(ET) for 90 min.  
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5.3.3 
Patient selection and consent. Patients admitted to the University of Kansas Hospital in 
Kansas City, Kansas following APAP overdose. The study protocol and design were 
approved by the institutional review board (IRB). Acute and chronic APAP overdose 
patients were from the emergency department or admitted to the intensive care unit with 
evidence of overdose. The diagnosis was made by a physician on site and all study 
subjects were required to sign a consent form. The inclusion criteria were two or more 
of the following: (1) patient-reported APAP overdose, (2) high serum APAP levels, and 
(3) abnormal liver function tests (based on ALT, AST, PT, bilirubin). Patients were 
excluded if there was reasonable evidence for liver injury due to another cause (viral 
hepatitis, ischemic liver, etc.). All overdose patients received standard of care NAC 
treatment. 
5.3.4 
Histology. Formalin-fixed tissue samples were embedded in paraffin and 5 m sections 
were cut. Sections were stained with hematoxylin and eosin (H&E) for blinded 
evaluation of the areas of necrosis by the pathologist. The percent of necrosis was 
estimated by evaluating the number of microscopic fields with necrosis compared to the 
entire cross sectional area. Additional liver sections were stained for neutrophils with 
anti-mouse neutrophil allotypic marker antibody (AbD Serotec, Raleigh, NC) as 
described in detail (Williams et al., 2010a). Positively stained cells consistent with 
neutrophil morphology were quantified in randomly selected high power fields (HPF, 
x400). Additional sections were stained for proliferating cell nuclear antigen (PCNA, 
Santa Cruz Biotechnology, Santa Cruz, CA) as described in detail (Chosay et al., 1998).  
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Positively stained hepatocytes were quantified in randomly selected high power fields 
(HPF, x400).  Additionally, some sections were stained for terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL, Roche, Indianapolis, IN) as described in 
detail (Lawson et al., 1999). 
5.3.5 
Isolation of hepatic non-parenchymal cells. The procedure was adapted from a method 
decribed by Watanabe et al. (34). Under isoflurane anesthesia mice were 
exsanguinated from the caudal vena cava into heparinized tubes and the blood was 
placed on ice.  The liver was immediately excised, placed in ice-cold PBS and minced 
with scissors.  The tissue was then pressed through a 200-gauge stainless steel mesh 
into a 50mL conical tube. The cell suspension was centrifuged at 50 x g for 2 minutes to 
remove hepatocytes and large debris. The supernatant containing non-parenchymal 
cells was then centrifuged at 350 x g for 5 minutes and cells were passed through a 40 
μm nylon screen and washed twice in a 15 mL conical bottom tube. Viable, nucleated 
cells were counted by trypan blue exclusion and brought to a uniform cell density.  
5.3.6  
Flow Cytometric Analysis of Neutrophil Function.  
5.3.6.1 
Neutrophil CD11b staining (Bajt et al., 2001; Daley et al., 2008). 5µg Fc receptor (FcR) 
blocking antibody (BioLegend, San Diego, CA) diluted in 100µL 0.1% BSA in PBS was 
added to 100µL non-parenchymal cell suspension for 20 minutes on ice (mouse only). 
To 50µL heparinized whole blood (mouse or human) or 200µL FcR-blocked hepatic 
non-parenchymal cells (mouse only), saturating concentrations of PE-Cy5-labeled-anti-
127 
 
Gr-1 [mouse only (BioLegend)] and PE-labeled-anti-CD11b [human or mouse 
(BioLegend)] diluted in 0.1% BSA in PBS were added. Tubes were incubated in the 
dark, on ice for 30 minutes. After washing with 0.1% BSA, red blood cells were lysed 
using RBC lysing solution (0.155 M NH4Cl, 10 mM KHCO3, 0.1 mM EDTA). Pellets were 
washed three times with 0.1% BSA then fixed with 2.5% buffered formalin. Samples 
were measured on the FACSCalibur (BD, Franklin Lakes, NJ). Mouse neutrophils were 
gated on the Gr-1high cells, which are the Ly6G-positive population and identified as 
neutrophils by cell morphology (Daley et al., 2008). Other leukocytes are either Gr-
1intermediate (mainly monocytes and eosinophils) or Gr-1negative (monocytes and 
lymphocytes) (Daley et al., 2008). Human granulocytes were gated to exclude 
monocytes and lymphocytes by forward- and side-scatter characteristics. The data were 
analyzed using the BD FACSDiva 6.0 software. 
5.3.6.2 
Reactive Oxygen Production (Emmendorffer et al., 1990; Smith and Weidemann, 1993). 
To 50 µL heparinized whole blood (mouse or human) or 100µL hepatic non-
parenchymal cells (mouse only), 2 µM phorbol 12-myristate 13-acetate (PMA) or saline 
was added and incubated for 10 minutes at 37ºC. 4 µM dihydrorhodamine-123 was 
added and incubated for 10 minutes at 37ºC. Ice-cold 0.1% BSA in PBS was added and 
pellets were washed. The non-parenchymal cell suspension was blocked with FcR 
blocking antibody (BioLegend) as previously described and cells were stained with 
saturating concentrations of PE-Cy5-labeled-anti-Gr-1 (BioLegend) diluted in 0.1% BSA 
(mouse only). Tubes were incubated in the dark, on ice for 30 minutes. After washing 
with 0.1% BSA, red blood cells were lysed using RBC lysing solution. Pellets were 
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washed three times with 0.1% BSA then fixed with 2.5% buffered formalin. Samples 
were measured on the FACSCalibur (BD) and the data were analyzed using the BD 
FACSDiva 6.0 software. 
5.3.6.3 
Neutrophil Phagocytosis (Sahlin et al., 1983; Bassoe et al., 1983) FITC-labeled E. coli 
particles (Life Technologies, Grand Island, NY) were opsonized in heat-inactivated 
pooled-normal human serum per manufacturer’s recommendation. To 50 µL aliquots of 
heparinized whole blood, 20 µL of diluted opsonized-FITC-E. coli were added and 
incubated for 5, 10, 15 and 20 min at 37ºC. Aliquots were then placed on ice and 0.4% 
trypan blue added to quench soluble and surface bound FITC-E. coli. Samples were 
measured on the FACSCalibur (BD) and the data were analyzed using the BD 
FACSDiva 6.0 software. 
5.3.7 
Statistics.  All results were expressed as mean  SE. Comparisons between 
multiple groups were performed with one-way ANOVA or, where appropriate, by 
two-way ANOVA, followed by a post hoc Bonferroni test. If the data were not 
normally distributed, we used the Kruskal-Wallis Test (nonparametric ANOVA) 
followed by Dunn’s Multiple Comparisons Test. P < 0.05 was considered significant. 
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5.4 Results 
5.4.1 Time course of APAP-induced hepatic injury 
It has been demonstrated that neutrophils do not contribute to APAP-induced liver injury 
with a multitude of genetic and pharmacologic interventions (reviewed in detail: 
Jaeschke et al., 2011).  We have also shown that 6h post APAP neutrophils in the 
peripheral blood and liver are not primed or activated (Chapter 4); additionally, 
increasing the hepatic accumulation of PMNs (with recombinant IL-1β or LPS) does not 
enhance injury (Chapter 2 and 4, respectively).  It has been demonstrated in many 
studies that neutrophils are recruited into the liver following APAP overdose, however 
the activation status of these leukocytes has never been evaluated; therefore a time 
course of hepatic injury and resolution was performed.  In C57BL/6 mice, following an 
i.p. dose of APAP (300mg/kg), there is substantial hepatic injury at 6 h and continues to 
increase until 24 h; at or around 24 h the injury resolution phase begins.  This is 
demonstrated by increasing plasma ALT until 24 h and rapidly decreasing plasma ALT 
beyond this time (5.4.1.1A).  Confirming the ALT data is hepatic necrosis scoring 
(5.4.1.1B) determined from H&E stained liver sections (5.4.1.1C).  The differences in 
plasma ALT and the total area of necrosis at 48 h and 72 h show no active injury but 
rather the resolution of injury.  Confirming this is TUNEL staining from representative 
mice (5.4.1.1D).  At 6 h, 12 h and 24 h increasing DNA damage can be seen.  The area 
and intensity of TUNEL staining at 48 h is much less, and by 72 h fragmented DNA is 
almost undetectable in the liver despite the presence of necrotic lesions. 
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5.4.1.1 
 
Hepatic injury and resolution following APAP overdose: C57BL/6 mice were treated with 
300 mg/kg APAP (i.p.) for 6, 12, 24, 48 or 72 h or with 100 μg/kg LPS for 90 min.  
Heparinized blood was used for the determination of plasma ALT (A).  Area of necrosis 
was quantified in blinded fashion by the pathologist from H&E stained liver sections (B).  
Representative liver sections (50x magnification) are shown (C).  TUNEL staining (100x 
magnification) shows increasing DNA damage within necrotic areas until 24 h and 
resolution of fragmented DNA at 48 and 72 h (D).  *P<0.05 compared to 0 h control. (n 
= 4-7 mice per group) 
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5.4.2 Hepatic neutrophil recruitment and hepatocyte regeneration 
It has been shown that the recruitment of neutrophils into the liver trails behind the 
progressing liver injury (Lawson et al., 2000).  If neutrophils were causing injury it would 
be logical to see the maximal number of neutrophils prior to the peak of injury, however 
the peak of neutrophil accumulation occurs at the peak of injury as resolution of injury 
begins (5.4.2.1A).  The hepatic accumulation of neutrophils can be seen at 6 h with 
most neutrophils located at the periphery of injury and in sinusoids of healthy tissue 
(5.4.2.1B).  At 12 h the total number of hepatic neutrophils continues to increase 
however the neutrophil distribution remains similar.  By 24 h the neutrophil count peaks 
with most neutrophils located within the necrotic lesions.  Forty-eight hours post 
overdose, the number of neutrophils decrease dramatically and continues to decline by 
72 h, however these neutrophils are located exclusively within the injured tissue.  As 
stated previously, the injury resolution (as determined by PCNA positive hepatocytes 
which identifies cells in S phase) begins around 24 h post-overdose in the mice 
(5.4.2.1C,D).  The peak of PCNA positive hepatocytes was observed at 48 h with many 
proliferating hepatocytes still observed at 72 h.  Additionally, this pattern was confirmed 
by western blotting for PCNA of total liver homogenate (data not shown).  The location 
of PCNA positive cells occurs mostly at the edge of necrosis and the recruited immune 
cells reside within this area. 
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5.4.2.1
 
Hepatic neutrophil accumulation and PCNA-positive hepatocytes following APAP 
overdose: Following APAP overdose hepatic neutrophils were identified by 
immunohistochemistry (IHC) and morphological features.  Neutrophil numbers 
increased during the injury phase until peaking at 24 h and decreased as injury is 
resolved (A).  Distribution of hepatic neutrophils changed throughout the time course 
(200x magnification).  Initially neutrophils could be observed in healthy and injured 
areas at 6 h and 12h.  At 24 h, 48 h and 72 h neutrophils could be seen exclusively 
within the necrotic areas (B).  Hepatocyte proliferation was quantified by counting 
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PCNA-positive cells and could not be observed prior to 24 h and peaked at 48 h (C).  
The distribution of PCNA-positive hepatocytes remained similar throughout the time 
course as shown by IHC (200x magnification) (D).  *P<0.05 compared to 0 h control. (n 
= 4-7 mice per group) 
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5.4.3 Hepatic and peripheral blood neutrophil priming and activation 
Phagocytic cells recruited into injured tissue can function in several roles: (1) 
phagocytose and remove cellular debris (2) produce factors that stimulate cell 
proliferation and (3) provide host defense from pathogens.  We have shown that the 
hepatic neutrophil counts correlate with injury resolution, so it was logical to determine if 
these neutrophils are activated.  In determining activation status we compared 
neutrophil reactive oxygen (ROS) priming and CD11b surface expression in both 
peripheral blood and hepatic neutrophils.  As an in vivo positive control, neutrophil 
activation from APAP-treated mice was compared to LPS-treated mice.  Following 
APAP overdose, peripheral blood neutrophils had increased CD11b expression at 12 h 
and 24 h (5.4.3.1A), which correlates with the highest levels of most circulating 
cytokines, chemokines and DAMPs following APAP overdose (Antoine et al., 2009; 
Chapters 3 & 4).  Correlating with increased CD11b on peripheral neutrophils, hepatic 
neutrophils also demonstrated increased CD11b expression, but this expression 
persisted much longer (5.4.3.1B).  This sustained hepatic neutrophil CD11b expression 
could have been caused by the local environment enhancing CD11b expression.  
Despite enhanced neutrophil CD11b expression in the blood and liver the magnitude of 
CD11b expression was much less than that observed following LPS treatment.  Blood 
neutrophil ROS priming was elevated at 24 h and remained elevated at 48 h, but was 
not increased over control during the injury phase at 6 h and 12 h (5.4.3.1C).  This ROS 
priming in the blood could be critical for host defense during liver function impairment.  
Interestingly, despite transient ROS priming in the blood no increase over control could 
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be observed in hepatic neutrophil ROS priming at any time during injury or liver repair 
(5.4.3.1D).   
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5.4.3.1 
 
Activation of peripheral blood and hepatic neutrophils following APAP overdose 
The activation status of neutrophils (Gr-1high population) was determined by surface 
CD11b expression and PMA-induced reactive oxygen production.  Overlaying the 
neutrophil activation status is plasma ALT to show the correlation with injury.  Peripheral 
blood neutrophils showed increased CD11b expression at only 12 h and 24 h (A).  A 
similar time course of activation could also be observed from liver neutrophils, however 
the neutrophils in the liver past the peak of injury also showed enhanced CD11b 
expression (B).  In peripheral blood neutrophils demonstrate ROS priming at 24 h and 
48 h (C).  Interestingly, no ROS priming was ever seen in liver neutrophils following 
APAP overdose (D).  *P<0.05 compared to 0 h control (for activation status only, ALT 
shown in Fig. 1) (n = 4-7 mice per group) 
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5.4.4 Liver regeneration in NADPH oxidase-deficient mice following APAP 
overdose 
Since C57BL/6 mice show no hepatic neutrophil ROS priming throughout the time 
course we used NADPH oxidase-deficient (gp91-/-) mice to confirm that phagocyte 
ROS was not critical for liver repair following APAP overdose.  In addition to neutrophils, 
monocytes and macrophages also lack respiratory burst in gp91-/- mice.  James et al. 
(2003) demonstrated that gp91-/- mice have no modulation of injury following APAP 
overdose but did not evaluate recovery from APAP-induced injury.  To evaluate this 
gp91-/- and C57BL/6 control mice were treated with APAP and sacrificed at 24 h, 48 h 
and 72 h.  Not surprisingly there was no difference in the peak of injury at 24 h between 
gp91-/- and C57BL/6 mice as measured by plasma ALT (5.4.4.1A) and necrosis scoring 
(5.4.4.1B) as determined by H&E staining (5.4.4.1C).  Additionally, at 48 h and 72 h the 
decrease in plasma ALT and area of necrosis was not different between genotypes.  
These findings demonstrate that despite the lack of functional NADPH oxidase the 
progression and resolution of injury is unaltered indicating removal of cellular debris by 
phagocytes does not require oxidative burst. 
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5.4.4.1 
 
Injury in gp91-/- (Phox-/-) and C57BL/6 control mice following APAP: Mice were treated 
with 300 mg/kg APAP (i.p.) for 24, 48 or 72 h.  Heparinized blood was used for the 
determination of plasma ALT (A).  Area of necrosis was quantified in blinded fashion by 
the pathologist from H&E stained liver sections (B).  Representative liver sections (50x 
magnification) are shown (C).  *P<0.05 compared to 0 h genotype control. (n = 3-4 mice 
per group) 
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5.4.5 Hepatic neutrophil recruitment and hepatocyte regeneration in gp91-/- mice 
It has been shown that inflammation and innate cell recruitment is altered in gp91-/- 
mice.  In peritonitis (Pollock et al., 1995; Rajakariar et al., 2009), bronchial inflammation 
(Morgenstern et al., 1997) and arthritis (van de Loo et al., 2003) gp91-/- mouse models 
there is increased and sustained innate immune cell infiltration.  Following APAP 
overdose in gp91-/- mice a marked increase in hepatic neutrophil recruitment could be 
observed versus C57BL/6 mice (5.4.5.1A).  This increase was most dramatic 24 h post-
overdose but still significantly elevated at 48 h; by 72 h, the difference in hepatic 
neutrophil counts between groups was not significantly different (5.4.5.1A).  The 
distribution of neutrophils was not altered between groups however.  In C57BL/6 mice at 
24 h most neutrophils are located within the necrotic lesions and the same was 
observed in gp91-/- mice (5.4.5.1C).  By 48 h and 72 h most neutrophils are even more 
centrally located within the necrotic tissue in both genotypes despite a substantial 
reduction in total counts.  Interestingly, despite this difference in inflammation the 
proliferation of hepatocytes was unaffected.  PCNA positive hepatocytes at each time 
were not different between genotypes (5.4.5.1B) and the pattern of positive cells was 
not different, with most PCNA-positive cells being observed adjacent to the injury (data 
not shown). 
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5.4.5.1 
 
Neutrophil recruitment and hepatocytes proliferation in gp91-/- mice: As shown 
previously, neutrophil quantification was determined by IHC.  Neutrophil recruitment in 
gp91-/- mice was markedly elevated over C57BL/6 controls at 24 h and 48 h (A).  The 
distribution of neutrophils was not different between genotypes, with most neutrophils 
accumulating with the areas of necrosis (B).  Quantification of PCNA-positive 
hepatocytes by IHC was not different between genotypes with the peak of PCNA-
positive hepatocytes being observed at 48 h post APAP (C). *P<0.05 compared to 0 h 
genotype control. #P<0.05 compared to time matched control. (n = 3-4 mice per group) 
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5.4.6 Human granulocyte activation following APAP overdose 
The neutrophil function in human overdose patients can only be evaluated in peripheral 
blood because there is no therapeutic benefit of liver biopsy especially in light of 
frequent coagulopathy in these patients.  Therefore the deleterious or beneficial role of 
neutrophils following APAP overdose must be determined from circulating neutrophils.  
To determine the activation status of neutrophils several priming or activation 
parameters were evaluated serially from freshly drawn heparinized whole blood, 
however limitations in sample collection and analysis did not permit us to evaluate these 
parameters daily. 
Three representative patients that fully recovered from APAP-overdose are presented in 
Figure 6.  Activation status was determined by granulocyte CD11b surface expression, 
phagocytic efficiency of FITC-labeled opsonized E. coli particles, and PMA- and 
opsonized E. coli-induced ROS production as determined by DHR123 to R123 
conversion.  Overlaying these activation parameters are plasma ALT levels indicating 
the progression and resolution of liver injury in these patients.  Two patients 
(5.4.6.1A,B) were admitted to the hospital prior to the peak of liver injury and one patient 
arrived at or after the peak of liver injury (5.4.6.1C).  The activation status of neutrophils 
(gating on the forward and side scatter properties of granulocytes) was determined by 
measuring the mean fluorescent intensity (MFI) of all neutrophils and normalized to the 
MFI of the first day sampled; therefore the data is shown as a fold-increase over the first 
day measured.  The patients represented in 5.4.6.1A and 5.4.6.1C had low neutrophil 
function parameters at or near the peak of injury that increased as the injury was 
resolving.  The patient represented in 5.4.6.1B had increasing peripheral blood 
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neutrophil activation as the injury was increasing, however this activation status 
continued to rise and remained elevated during resolution until he was discharged from 
the hospital nine days post-admission. 
From the representative patients shown (5.4.6.1) the trend is clear that the activation of 
neutrophils continues well after active liver injury has subsided and in most cases 
begins after the injury phase.  In total, ten patients with liver injury (ALT: >800 U/L) that 
ultimately fully recovered after APAP-overdose have been evaluated and are presented 
(5.4.6.2).  At or near the peak of liver injury (highest measured plasma ALT), plasma 
ALT and neutrophil function tests 72 to 96 hours after the peak of injury (as determined 
by sample availability) were compared.  These declining ALT values are shown 
(5.4.6.2A).  Consistent with the representative patients no correlation between declining 
injury and CD11b expression was observed (5.4.6.2B).  Reactive oxygen priming that 
was induced by PMA (5.4.6.2C) and opsonized E. coli (5.4.6.2D) was significantly 
increased following the peak of injury.  The phagocytic rate of neutrophils showed a 
trend toward increased activation but with this sample size was not significantly 
increased. 
These preliminary data demonstrate an increasing neutrophil function in patients that 
recover from APAP overdose.  Some patients show increasing PMN activation prior to 
injury however most patients evaluated thus far show activation following the peak of 
injury.  These findings show the possibility that neutrophils could aid in injury resolution 
via the removal of cellular debris or enhanced host defense functions. 
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5.4.6.1
 
Neutrophil function in representative human APAP overdose patients: Three 
representative patients are shown.  Progression and resolution of liver injury is 
presented as plasma ALT.  Gating on the granulocyte population (predominantly 
neutrophils) the activation status was determined by CD11b expression, rate of 
phagocytosis of FITC-labeled E. coli, and PMA- and E. coli-induced ROS production. 
(A) Patient 1 was admitted to the hospital prior to the peak of ALT and neutrophil 
function tests were performed on days 2, 3, 4 and 8.  The patient was discharged on 
day 8.  (B) Patient 2 was admitted prior the peak of injury and neutrophil function tests 
were measured on days 1, 2, 4 and 9.  The patient was discharged on day 9.  (C) 
Patient 3 was admitted at or shortly after the peak of liver injury and neutrophil function 
tests were measured on days 2, 6, 7 and 12.  The patient was discharged on day 12. 
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5.4.6.2
 
Comparison of neutrophil function in human APAP overdose patients at the peak of 
injury and during liver recovery: Ten patients with moderate to severe liver injury that 
fully recovered from APAP-overdose were evaluated for neutrophil activation at or near 
the peak of liver injury and then again 3-4 days later (depending on sample availability).  
All flow cytometric data are presented as mean fluorescent intensity (MFI) of the total 
granulocyte population. (A)  Three to four days post overdose all patient plasma ALT 
values declined.  (B)  Peripheral blood neutrophil CD11b expression did not change 
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during this time.  (C) PMA-induced reactive oxygen priming was elevated post-injury.  
(D) Similarly, E. coli-induced reactive oxygen priming was elevated post-injury as well.  
(E) A trend toward enhanced phagocytosis of FITC-labeled opsonsized E. coli was seen 
post-injury.  Post-injury data shown were measured at 72 h (n = 6) and 96 h (n = 4).  
*P<0.05 as determined by paired-Students T-test. 
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5.5 Discussion 
It is well established in the mouse model of APAP-overdose that innate immune cells, in 
particular neutrophils, do not contribute to the progression of injury.  Due to the many 
functions of neutrophils, including host defense from invading pathogens and removal of 
cellular debris, it was important to characterize the neutrophil activation status following 
APAP overdose.  NADPH oxidase-mediated ROS production is the primary mechanism 
used by neutrophils to cause cellular injury during endotoxemia (Gujral et al., 2004) and 
ischemia-reperfusion injury (Hasegawa et al., 2005).  Despite numerous studies 
investigating the role of NADPH oxidase during injury, it has not been previously 
demonstrated if NADPH oxidase is or is not critical for resolution of acute liver injury. 
5.5.1 Role of gp91 during inflammation 
NADPH oxidase-deficient mice in various models of injury show prolonged inflammation 
and impaired injury resolution. It has been shown that sterilized fungal preparations 
administered to gp91-/- mice were capable of causing a chronic bronchopneumonia with 
profound neutrophil infiltrates into the lung and prolonged elevations in inflammatory 
cytokines (Morgenstern et al., 1997).  In other models of sterile inflammation, peritonitis 
was induced with thioglycollate (Pollack et al., 1995) or zymosan A (Rajakariar et al., 
2009); in these models gp91-/- mice had increased numbers of neutrophils (two- to 
three-fold increase) and these neutrophils remained in the peritoneal exudate longer 
than control mice.  Zymosan was also able to induce a more robust and prolonged 
inflammation marked with neutrophil infiltrates in a phox-deficient mouse arthritis model 
(van de Loo et al., 2003). These increases in neutrophils infiltration was not due to 
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enhanced peripheral blood counts or altered chemotaxis (Pollock et al., 1995).  It was 
hypothesized that chronic inflammatory response in gp91-/- mice could be due to 
inefficient debris clearance or the inability to inactivate chemotactic signals (Pollock et 
al., 1995). Clearly from the neutrophil counts following APAP overdose there is an 
enhanced inflammatory response in gp91-/- mice but no effect on injury or injury 
resolution could be observed.  Additionally the disappearance of neutrophils occurred 
quickly with no difference from C57BL/6 mice by 72 h post-APAP. 
5.5.2 Innate immune function during APAP overdose 
It is well know that during acetaminophen overdose liver function is greatly impaired 
resulting in decreased production of complement components including C3, C4 and C5 
(Wyke et al. 1980; 1982) and an increased susceptibility to infection (Wyke, 1987).  This 
decrease in innate immune defense could prompt a compensatory response of 
enhanced neutrophil activation.  It was reported that neutrophil ROS production was 
reduced in APAP overdose patients that have progressed to acute liver failure 
(Clapperton et al., 1997) however the neutrophil activation was only evaluated at one 
time point and did not evaluate if patients that recover from severe liver injury have 
modulation of neutrophil function.  Subsequent studies evaluated the efficacy of 
recombinant G-CSF administration to APAP-induced ALF patients (Rolando et al., 
2000a; 2000b).  In these studies neutrophil function was restored as determined by 
enhanced phagocytosis and bacterial killing both in vivo and in vitro.  Following 
standard of care, all APAP-overdose patients were receiving N-acetylcysteine (NAC). It 
has been reported that NAC alters respiratory burst and phagocytosis in neutrophils, 
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however these studies were performed in critically ill patients with sepsis or systemic 
inflammatory response syndrome (Heller et al., 2001). As NAC is the standard of care 
for APAP overdose patients this not a variable that can be eliminated in the human 
studies. 
APAP overdose patients that progress to fulminant hepatic failure have very severe 
(<20% normal activity) deficiencies of serum complement factors resulting in severe 
defects of in vitro test with phagocytosis as an endpoint (Wyke et al. 1980).  
Additionally, it has been established that during acute liver failure the ability of 
neutrophils to produce ROS was reduced and partially attributable to impaired 
opsonization (Clapperton et al. 1997).  Our current study did not evaluate opsinization in 
the study design.  Opsinization of E. coli and FITC-labeled E. coli was done with pooled 
normal human serum to only evaluate neutrophil priming and not complicate results with 
potential impairment of patient complement components.  
5.5.3 NADPH oxidase is not needed for injury resolution 
From the data generated it is clear that NADPH oxidase mediated ROS production is 
not a critical function in removal of cellular debris.  This was demonstrated by a lack of 
ROS priming observed in hepatic-sequestered neutrophils and confirmed in NADPH 
oxidase-defective mice.  Despite this lack of ROS priming in the liver, priming was 
observed in peripheral blood; it is not clear if this priming was compensatory due to 
impaired host defense or a secondary effect from circulating cytokines or DAMPs.  In 
human overdose patients this enhanced neutrophil function could be critical to prevent 
infection or simply function as a biomarker of positive patient outcome.  Clearly there 
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appears to be link between peripheral neutrophil activation and favorable outcome, 
however more patients need to be evaluated to draw more substantial conclusions. 
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6 Conclusions and future directions 
Acetaminophen overdose can be divided into various stages. The injury phase is 
composed of two parts, the initiation and propagation phases (discussed in detail in 
Chapter 1).  As the injury begins to peak, the regenerative processes begin to repair the 
damaged tissue.  This involves replication of lost hepatocytes, removal of damaged 
cells and extracellular debris and the reformation of normal liver architecture.  From our 
data and the data of multiple other groups, the lost hepatocytes mass is replenished by 
surviving adjacent hepatocytes. Ultimately, these processes repair the liver completely 
without any adverse long term effects. The mechanisms and orchestration of all these 
processes (especially tissue repair) during and after APAP overdose have yet to be fully 
explained. 
This dissertation shows that IL-1β is produced during APAP overdose in a caspase 
dependent manner which can be inhibited in vivo by the use of pan-caspase inhibitor.  
Preventing the maturation of IL-1β protein by inhibiting the Nalp3 inflammasome and 
caspase-1 does not alter the APAP-induced injury nor does it alter hepatic neutrophil 
recruitment.  Additionally, IL-1 receptor deficient mice are not protected from APAP 
induced injury.  The use of supra-physiological doses of recombinant IL-1β or large 
doses of endotoxin can greatly enhance the number of neutrophils recruited into the 
liver however the injury is not altered by this influx.  This further confirms the benign role 
of neutrophils in the APAP injury process.  Quantitative assessment of neutrophil 
activation was also performed during APAP overdose and during endotoxemia as a 
positive control.  During the early injury phase neutrophils are not primed or activated in 
the blood or in the liver.  As the injury phase ends and the regeneration phase is more 
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apparent neutrophils show enhanced activation and priming.  This activation is then 
sustained for several days as the injury is repaired.  Similar activation and priming can 
be seen in human APAP overdose patients.  It is not clear if the neutrophils participate 
in the injury resolution or if they provide enhanced host defense during the period of 
impaired hepatic function. 
The mechanism of APAP hepatotoxicity is dominated by intracellular events including 
the formation of a reactive metabolite, GSH depletion, and protein adduct formation, 
which initiates a mitochondrial oxidant stress and peroxynitrite formation. Ultimately, this 
oxidant stress and peroxynitrite are responsible for the MPT, nuclear DNA 
fragmentation and necrotic cell death. The subsequent release of DAMPs results in 
activation of Kupffer cells with cytokine and chemokine formation and recruitment of 
neutrophils and monocytes into the liver. Despite the substantial sterile inflammatory 
response after the initial cell death, there is no convincing experimental evidence to 
support the hypothesis that Kupffer cells, neutrophils or monocytes directly cause cell 
injury by producing cytotoxic mediators. In contrast, pro-and anti-inflammatory cytokines 
produced mainly by activated Kupffer cells (M1) modulate intracellular mechanisms of 
cell death by regulating gene expression of iNOS, heat shock proteins, heme 
oxygenase and others. In addition, monocyte-derived macrophages (M2) and potentially 
neutrophils are instrumental in removing necrotic cell debris and promoting hepatocyte 
proliferation ultimately resulting in tissue repair and resolution of the inflammatory 
response. Thus, in contrast to other acute injury models the innate immune response 
after APAP-induced liver cell injury is mainly beneficial and is well orchestrated to assist 
in the repair of the tissue damage.     
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Future additional work needs to be done to more completely understand the liver repair 
mechanisms after APAP overdose.  If treated early enough the survival rate is 
exceptionally high and it is possible to completely prevent injury even after a massive 
overdose.  It seems unlikely that a better, more cost effective antidote will be discovered 
to replace NAC.  NAC is very efficient at scavenging the reactive metabolite and 
subsequent oxidative stress.  Most likely improvement of patient outcome will occur by 
promoting liver growth and repair. 
The outcome after liver injury cannot be efficiently predicted by the measurement of 
serum transaminases.  Patients with very high AST/ALT will recover completely while a 
patient with a similar overdose will have much lower transaminases but ultimately die.  
This points to two possible reasons: 1) the patient in the first case, despite high ALT, 
still has a larger proportion of functioning liver mass and is therefore able to recover, or 
2) the second patient is unable to regenerate functional hepatic mass and ultimate dies 
because of it.  If most functional hepatocytes are lost the only hope for these patients is 
to replace dead hepatocytes. 
Currently there are multiple liver assist devices (LAD) being used clinically.  There are 
two main types of these devices.  The first and most commonly used are artificial liver 
support systems that utilize dialysis membranes and albumin or activated charcoal to 
remove toxins.  The second type of LAD uses human hepatoblastoma cells or porcine 
hepatocytes in a matrix exposed to patient blood or plasma which attempts to simulate 
and replace liver function lost during ALF.  In theory this will allow for the not only the 
removal of toxins but also replace the liver’s synthetic and metabolic functions.  These 
bioartifical liver systems are still in their infancy and time will tell if these can improve 
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patient outcome.  In theory these devices could decrease the burden of the remaining 
liver mass to help promote liver repair. 
Currently in the clinic the search for better predictors of patient outcome is a primary 
goal.  Recently the use of serum alpha-fetoprotein (Schmidt and Dalhoff, 2005) showed 
promise as a good predictor of patient outcome.  Our preliminary data in patients shows 
enhanced neutrophil activation in surviving patients.  Potentially this could serve as a 
functional biomarker of patient survival, but more data needs to be collected to confirm 
this finding. It has been known for decades that during fulminant hepatic failure innate 
immune function, and neutrophil function in particular, is impaired (Wyke et al., 1980; 
Clapperton et al., 1997).  The use of G-CSF in patients showed a restoration of 
neutrophil function however these studies were of insufficient size to determine patient 
outcome (Rolando et al., 2000a,b).  It is still possible that this treatment could have 
beneficial outcomes in larger studies.  
Repair is the most important factor in ultimate survival from APAP-induced ALF.  During 
acute injury hepatocyte mass is replaced by the replication of differentiated hepatocytes 
and not from liver progenitor cells (Malato et al., 2011).  Determination of how to 
stimulate the proliferation of remaining hepatocytes could be very useful clinically.  It 
has been shown in animal models that the cytokines produced during APAP overdose 
can modulate injury, it is not hard to believe that cytokines could also modulate tissue 
repair following APAP overdose.  Orchestration of these processes will be complex, so 
the use of animal models is essential to determine how these cytokines can modulate 
various pro-survival/pro-proliferative pathways within the hepatocytes. 
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It is still not clear how neutrophils could be participating in the injury resolution after 
APAP-overdose.  This could be occurring through various mechanisms: 1) the most 
straightforward mechanism would involve phagocytosis and cleanup of damaged tissue, 
2) enhanced immune surveillance and prevention of infection in the periphery, or 3) 
production of pro-regenerative factors that could act directly on hepatocytes or other 
hepatic cells (6.1).  
To better understand these mechanisms more experiments need to be performed in the 
mouse model.  This could be accomplished by depleting mice of neutrophils and 
observing hepatocytes proliferation and liver regeneration.  This depletion could be 
achieved by neutropenia-inducing antibody or genetic elimination of G-CSF or the G-
CSF receptor.  If neutrophils are essential for removal of damaged tissue these mice 
should have delayed or prevented liver recovery.  If defective regeneration was 
observed it would also be useful to compare the cytokine milieu produced in these mice.  
We have shown that CD18 is not essential for neutrophil recruitment into the liver, 
however hepatic sequestered neutrophils show enhanced CD11b expression.  Using 
CD18-deficient mice we could determine if this is essential for cleanup after APAP 
overdose.  Without CD18 leukocytes lose functionality of Mac-1 (CD18/CD11b); it is 
unknown if this plays an essential role in injury resolution.  It is possible Mac-1 prolongs 
neutrophil half-life in the tissue or enhances phagocytic rate of these cells. 
Early events in pathophysiology generally impact the later events.  The primary reason 
for sterile inflammation is to limit injury and promote tissue repair.  Occasionally, 
unchecked inflammation is deleterious; however this is not the case with APAP 
overdose. The inflammation does not make the injury worse; in fact it most likely helps 
155 
 
to resolve injury by creating an environment to promote repair and regeneration.  We 
have shown that IL-1β on its own is produced in insufficient quantity to modulate injury 
during APAP overdose; however acting in concert with other inflammatory mediators it 
helps recruit leukocytes into the liver.  These cells become activated in the blood and 
the liver and have functions which still need to be determined.  Better understanding of 
immune activation during late stage liver injury will be critical to predict patient outcome 
(need for transplantation) and improve survival rates.  Advances in this field will 
hopefully decrease the morbidity and mortality of the leading cause of acute liver failure 
in the US. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
156 
 
6.1 
 
Sterile inflammation is initiated by the release of DAMPs from injury hepatocytes.  This 
results in cytokine/chemokine-induced leukocyte recruitment.  We have shown these 
innate immune cells do not contribute to the injury but may be essential in tissue repair.  
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